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 Abstract 
Bacteria have existed on earth for 3.5 million years and their ability to 
evolve has allowed for their survival in almost all global niches. Bacteria 
evolve and adapt easily due to their short generation times, plastic genomes, 
acquisition (external) DNA and their ability to form protective bacterial 
communities i.e. biofilms or dormant metabolic states.  
 
Antibiotic drugs are currently our best medicine to treat (against) bacterial 
pathogens due to antibiotics unique properties of being small molecules that 
are soluble and act systemically. These qualities allow for many modern 
medical procedures to occur due to antibiotics preventative/ prophylactic and 
therapeutic qualities.  
 
Despite bacterial antibiotic resistance mechanisms always being present in 
nature, the overuse and misuse of antibiotics by humans are accelerating the 
rise and dissemination of bacterial antibiotic resistance. Bacterial antibiotic 
resistance is global threat to public health; especially because of lack of new 
drugs. It has been highlighted that understanding antibiotic resistance by 
further elucidating mechanisms of evolution, molecular mechanisms of ac-
tion and reservoirs of resistance are essential Therefore, the work involved in 
this PhD thesis, examines the evolution of antibiotic resistance in bacterial 
populations.  
 
Two main studies were performed: the first to elucidate the molecular mech-
anisms of collateral sensitive drug pairs and collateral resistance drug pairs 
in adaptation of Escherichia coli populations; and the second exploring mu-
tant variant dynamics in cystic fibrosis lung,  by analyzing sputum samples 
from chronic carriers of Pseudomonas aeruginosa undergoing antibiotic 
treatment. 
 
Both studies explore the trajectories of antibiotic resistance within bacterial 
populations: the first study by exploring antibiotic resistance loci, and the in 
the second by whole-gene sequencing. The desired outcome from both stud-
ies is to find methods to use antibiotic therapy more rationally to treat infec-
tion efficiently and effectively whilst reducing the evolution of antibiotic 
resistance. 
 Dansk resumé 
Bakterier har eksisteret på jorden i 3,5 millioner år, og i den tid har deres 
evne til at udvikle sig tilladt deres overlevelse i stort set alle tænkelige ni-
cher. Bakterier udvikles og tilpasses let på grund af deres korte generations-
tider, plastiske genomer, erhvervelsen af eksternt DNA samt deres evne til at 
danne beskyttende bakterielle samfund dvs. biofilm. 
 
Antibiotika er i øjeblikket vores bedste medicin til behandling af bakterielle 
patogener på grund af dets opløselighed systemiske virkning. Disse kvalite-
ter er vitale for mange moderne medicinske procedurer på grund af antibioti-
kas profylaktiske og terapeutiske egenskaber. 
 
På trods af at antibiotika resistensmekanismer altid har været til stede i natu-
ren, har samfundets overforbrug og misbrug af antibiotika fremskyndet stig-
ningen og formidling af bakteriel antibiotikaresistens. Bakteriel antibiotika-
resistens er en global trussel mod den offentlige sundhed; især på grund af 
manglen på nye lægemidler. En grundigere forståelse af antibiotikaresistens 
ved yderligere at belyse evolutionsmekanismer, molekylære virkningsmeka-
nismer og reservoirer er afgørende. Derfor belyser dette PhD-arbejde udvik-
lingen af resistens i bakterielle. 
 
To hovedundersøgelser blev udført: den første bestod i, yderligere at belyse 
de molekylære mekanismer i antbiotikapar som indbyrdes forstærker eller 
svækker resistensevolution i Escherichia coli populationer. Det andet studie 
udforsker mutantvariant dynamik i CF lunge-prøver fra kronisk Pseudomo-
nas aeruginosa inficerede cystisk fibrose patienter under igangværende anti-
biotisk behandling på hospitalet. Begge undersøgelser udforsker udviklings-
veje for antibiotikaresistens i bakterielle populationer: det første studie ved 
at udforske kendte antibiotikaresistensmutationer i genomet, og det andet 
ved sekventering af hele gener involveret i resistens. Det ønskede resultat fra 
begge undersøgelser er at finde metoder til at bruge antibiotika, der både 
behandler patogen effektivt og samtidig hindre udviklingen af 
antibiotikaresistens. 
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Outline of PhD Thesis 
This thesis is composed of 5 chapters: Bacterial Evolution, Antibiotic drugs, 
Profiling and Exploring Drug Treatment and Resistance, Applications of 
Profiling of Drug Treatment and Resistance, and Concluding Remarks and 
Future Perspectives.  
 
Each chapter composes of a short introduction, to provide the overview of 
the importance of the chapter, followed by sub-chapters. Within each of the 
sub-chapter’s ideas, theories and links to scientific literature are given and 
then summarized with how this applies to the to the research work done in 
this PhD time-period.  
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Bacterial Evolution 
 
Within most natural environments a diverse consortia of bacteria species 
exist. Following the evolutionary laws of nature, bacteria have adapted to a 
variety of physiological demands such as pH [1], osmotic pressures [2], tem-
perature [3], nutrient availability [4] and chemical perturbations like disin-
fectants [5], metal ions [6] and antibiotics [7]. Bacteria have several evolu-
tionary constraints e.g. asexual reproduction that limits chromosomal ge-
nomic recombination and a high codon bias genome of ca. 90% [8]. Despite 
these constraints, bacteria can easily and rapidly evolve due to their short 
generation time (e.g. E. coli K-12 sub-strain MG1655 in Luria-Bertani broth 
at 37oC has a doubling time during steady-state of 20 minutes [9]), their 
large population size capability (e.g. up to 2x109 CFU/mL [10]), their rate of 
spontaneous mutation (e.g. ~ 0.03 per genome per replication [11]), and their 
genetic exchange between taxa [12]). These advantageous characteristics 
promote both anagenesis, which allows evolution within the bacterial species 
population, and cladogenesis, which allows new bacterial species to develop 
in different biological niches [13].  
Processes that allow bacterial genomic modification  
To accomplish these abilities, bacteria rely on mechanisms to acquire novel 
genetic information and manipulate their genome. This achieved by three 
main processes: bacterial transduction, transformation and de novo muta-
tions. The first two processes occur by horizontal gene transfer (HGT), 
which unlike other forms of life defy species specific boundaries. Therefore, 
a microbial habitat can quickly possess abilities to defy the abilities of given 
antimicrobials, metal ions and disinfectants. An infamous example of this is 
the CTX-M-15 plasmid that confers resistance to antimicrobials, metal ions 
and biocides [14]. Furthermore, it is easily disseminated in Enterobacteri-
aceae and as a consequence several clinical outbreaks have occurred [15–
17]. De novo mutations, however, occur intrinsically within a cell and if 
remain uncorrected by cellular correction systems these mutations will be 
passed on to its future daughter cells. As mentioned earlier HGT resistance 
mechanisms defy species specific boundaries.  It could therefore be easy to 
assume that more scientific effort should be concentrated on HGT resistance 
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mechanism rather than de-novo mutational resistance mechanisms, however 
both play an integral role in adaptation evolution. For some bacterial species 
– such as P. aeruginosa in chronically infected cystic fibrosis patients 
[18,19] and Mycobacterium tuberculosis where HGT [20] – evolution is 
generated mainly or solely by the latter mechanism. Therefore, scientific 
research in both types of acquired resistance are important, especially when 
it comes to understanding bacterial evolution in a wide range of organisms 
and perturbations. 
 
With the research involved in this PhD doctorate, I have looked into the 
types of de novo mutations that occur in the bacterial population. De novo 
mutations are a result of genomic instability. Genomic instability is induced 
by the constant threat that bacterial cells are exposed to, such as operations 
of their DNA replication and repair systems, mobile elements, phages, chem-
ical entitles and environmental factors [21]. De novo mutations manifest 
themselves as point mutations, genomic rearrangements or translocations, 
and can be inherited to future prodigy if remained un-corrected by cellular 
repair systems. Point mutations, or single nucleotide changes (SNPs), can 
induce three types of amino acid coding changes. The effects of these chang-
es are silent, when no effects are observed to coding amino acid, missense, 
where a different amino acid is coded for and is also referred to as a non-
synonymous change, and nonsense mutations, which encodes for a stop-
codon that terminates the transcription of the RNA prematurely. Genomic 
rearrangements are induced by insertion or deletions sequences (INDELs) or 
the combination thereof, amplifications, or translocations. The result of IN-
DELs in the genome cause change to the encoded amino acid sequence of a 
transcribed mRNA strand by either the addition or subtraction of codons or 
by causing frame shifts to encode entirely different amino acids. The results 
of gene duplication are common in both bacteria and eukaryotes [22]. A 
possible model for gene duplication is the innovation-amplification-
divergence model. In this model an ancestral gene has a weak secondary 
activity, and in a given favorable selection pressure a cell that duplicate this 
gene create a different gene from the ancestor by genetic modification [23]. 
From the research work performed during this PhD, my main focus was on 
missense and nonsense mutations SNPs, INDELs and possible gene duplica-
tion events that occur during antibiotic adaptation or during antibiotic treat-
ment. 
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Evolutionary theory: Neo-Lamarckism versus Neo-
Darwinism? 
Genomic modifications which lead to bacterial phenotypes that are better 
suited to a given environment are essential for bacterial evolutionary devel-
opment, but which evolution hypothesis that induce these effects is uncer-
tain. Therefore, the theory that best answer the evolutionary development 
process is under scientific debate again, as the impact of understanding pro-
cess that lead to genomic stability play an important role in curbing antibi-
otic resistance. 
 
The two main theories are Neo-Lamarckism and Neo-Darwinism. The Neo-
Lamarckism theory assumes that external environmental cues causes indi-
viduals to change their phenotype in response. Individuals that are successful 
in changing their phenotype to adapt will pass this on to their future progeny. 
The Neo-Darwinism theory follows that the basic unit of evolution is a 
population, where genomic variation occurs by random genetic drift and 
selection for given phenotypes is driven by environmental factors. Evidence 
for both theories has been produced by the use of next generation sequencing 
(NGS) and other typing methods. Direct evidence for bacterial Neo-
Lamarckism can be found in the CRISPR-cas system, where integration of 
small segments of HGT DNA into specific loci allows for host defense 
(Koonin and Wolf 2009). Most de-novo antibiotic resistance is nonetheless 
assumed to be the result of Neo-Darwinism. This is seen in bacterial popula-
tions where contact with sub-lethal concentrations of antibiotics generates 
random mutants either by inducing direct effects (e.g. bleomycin inducing 
double-strand DNA breaks [24]) or in-direct effects (e.g. ampicillin down-
stream production of reactive oxygen species (ROS) that incudes DNA dam-
age [25]). These mutations establish themselves in the population and can be 
fixed or lost in the bacterial population by clonal interference. However, a 
quasi-Lamarckism mechanism coupled with neo-Darwinian mechanism, 
permits bacterial cell to adapt to various environmental perturbations by 
allowing a regulation of genomic instability to occur followed by natural 
selection [26]. The quasi-Lamarckism mechanism was first suggested by 
Radman, circulated privately in 1970, where she states that “‘SOS-
replication’ mechanism can be induced by a variety of mutagenic treatments, 
which cause inhibition of ‘vegetative’ DNA replication…This replication 
mechanism is an inaccurate, mutation-prone process” (Embedded in [27]). 
Interestingly many antibiotic drugs classes used in the experimental work of 
this PhD thesis also induce SOS- replication response. The drug classes that 
induced these effects are: aminoglycosides [28], chloramphenicol [29] and 
fluoroquinolones [30]. Therefore, it is interesting to note that, sub-lethal 
exposure to antibiotics can induce DNA damage and trigger genomic insta-
bility that therefore induced genetic diversity of microbial pathogens 
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(Shapiro 2015). Despite none of these quasi-larmarckian mechanisms being 
validated experimentally in this PhD thesis, the neo-Darwinian mutations I 
observe could also be a result of the antibiotics inducing genomic instability 
facilitated by quasi-larmarckian mechanisms. Therefore, this is something I 
would like to return to in the concluding remarks and future perspectives. 
Bacterial population adaptations to novel environmental 
challenges 
For bacteria populations to adapt to a new environmental challenge or per-
turbation, novel mutation cells must occur, reproduce in quantities as not to 
be lost by random genetic drift. This process is known as bacterial mutant 
allelic establishment, where a sub-population of this clone type develop 
within a population. If this mutant allelic sub-population is able to take over 
the population and dominate 100% of the population this is known as fixa-
tion. 
 
Two variables govern a bacterial population’s ability to survive a new envi-
ronmental challenge these are: the range of beneficial mutations that are able 
to be produced in the population and the size of the population [31]. In a 
small bacterial population, the range of beneficial mutants is less, therefore 
that population has less likelihood of surviving is also less [32]. However, if 
a beneficial mutation allelic sub-population does arise and become estab-
lished it has an almost certain probability of fixing in the population. This is 
opposite in larger population due to the range of beneficial mutations being 
higher (e.g. clonal divergence), so likelihood of surviving is also higher. 
However, the beneficial mutation allelic sub-population or clone has less 
chance of becoming fixed in the population. This is due to clonal interfer-
ence, where two novel genotypes or more compete with each other to estab-
lish themselves within the population [33]. Different genotypes can occur in 
different genetic backgrounds within the population, therefore the large the 
bacterial population, the higher diversity in bacterial genetic background and 
novel beneficial mutational allelic types [34]. All these characteristics play 
an important role in evolution population mutagenic allelic dynamics, where 
periodic selection of various clones of mutant alleles occur. The overall re-
sult of clonal interference in a large population acts as a natural selection 
process that selects beneficial mutations that has the largest effect at the 
smallest fitness cost, known as periodic selection [35].  
 
The work I presented in this PhD thesis explores the characteristics of evolu-
tion of bacterial population mutagenic allelic dynamics by time-resolved 
tracking known mutagenic loci in in-vitro antibiotic E. coli adaption (manu-
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script I) or in known antibiotic genes of P. aeruginosa of chronically infect-
ed cystic fibrosis patients under going 14 days of antibiotic treatments (man-
uscript II). From these results, I see in the bacterial populations strong evi-
dence of clonal divergence, clonal interference and periodic selection, how-
ever by the methods use I can not confirm the genetic backgrounds these 
beneficial mutations and can not confirm any historical contingency events. 
Interactions I see within my populations are summarized in (Fig 1).  
 
 
Fig 1. Summary of generalized population mutant variant interac-
tions (A) Population size effect (i) small bacterial population under selec-
tion, (ii) large bacterial population under selection. (B) Mutation variant 
interactions (i) clonal interference events, (ii) super-imposing establishment 
events, (iii) population fixation events. 
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Antibiotic drugs 
The discovery and use of antibiotic drugs allowed the birth of modern medi-
cine to occur by allowing medical procedures to be performed whilst reduc-
ing the risk of pathogenic bacteria. Antibiotic drugs are currently our best 
medicine to treat against bacterial pathogens due to antibiotics’ unique prop-
erties of being small molecules that are soluble and act systemically [36]. 
Bacteria have a tremendous ability to evolve and develop genotypes to over-
come antibiotic drug effects, and when this occurs in invading bacterial 
pathogens they cause mortality and morbidity. It is essential to understand 
where antibiotic drugs come from, what classes of drugs we have, how bac-
teria become resistant to these drugs and how we can counteract the effects 
of antibiotic resistance. 
Discovery of antibiotics 
The potential of antibiotics was first demonstrated following the discovery 
and use of salvarsan, which was used in the first antibiotic drug trial of late 
stage syphilis patients and where impressive outcomes were observed [37]. 
Antibiotic discovery and use was further invigorated by the discovery of 
penicillin from a contaminated agar plate by Alexander Flemming [38]. Fol-
lowing the purification steps developed by Florey and Chain, the medicinal 
use of penicillin came into fruition[39]. The importance of this discovery 
was that microorganisms themselves had the ability to produce small chemi-
cal compounds that inhibited or killed other microorganisms. This led to the 
Golden era of antimicrobial discovery with most success being discovered 
by the Waksman antimicrobial discovery platform [40]. Following the boom 
in antibiotic discovery it was naively believed that chemistry would be able 
to produce novel antimicrobials. This approach generated fewer effective 
novel antimicrobials than expected at the time, but did generate better for-
mulations, drug penetrations and drug delivery [41]. The impact of this cre-
ated the antibiotic discovery deficit (Fig 2), and – coupled with the rise in 
antibiotic resistance – there is now a strong emphasis to discover novel anti-
biotics but also to further our understanding of our current antibiotics to op-
timize their use. The research involved in this PhD thesis of profiling drug 
resistance, in both the laboratory and from the clinical setting, aims at under-
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standing bacterial antibiotic resistance evolution with the long-term goals of 
using antibiotics more effectively. 
 
 
Fig 2. Time-line of antibiotic drug introduction date 
Antibiotic Classes 
To further understand our current antibiotic drugs it is important to know 
their chemical structure, as drugs that have the same structural class tend 
exhibit similar traits of effectiveness, toxicity and allergy potential [40]. 
Using structural chemistry to classify antibiotic drugs allows us to construct 
a generalized view of which antibiotic classes disrupt particular biological 
processes in the bacterial cell (Fig 3). Overall antibiotics disrupt three bio-
logical structures and synthesis processes essential for cell growth and 
maintenance. These are cell structure synthesis and maintenance, nucleic 
acid synthesis and protein synthesis. Further categorization can be done on 
the anitbiotic’s other traits, such as their bacterial effect (i.e. bactericidal or 
bacteriostatic), the type of pathogens they target (i.e. Gram negative or posi-
tive or both), the spectrum of pathogens they target (i.e. narrow or broad-
spectrum) and their pharmacological abilities. The classification and antibac-
terial traits of all antimicrobials are vital to know to be able to utilize these 
drugs to their maximum efficacy. 
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Fig 3. Generalized view of biological processes disrupted by different an-
tibiotic classes. Top left are antibiotics that disrupt protein synthesis, top 
right is antibiotics that disrupt cell structure and maintenance and bottom 
right antibiotics that disrupt nucleic acid synthesis. 
Antibiotic Resistance and Persistence 
As previously mentioned bacteria have a tremendous capacity to evolve and 
overcome several survival limiting environmental factors. It is therefore no 
surprise that they also evolve to resist antibiotics. Antibiotic resistance from 
a bacteriologist perspective is the genetic adaptation of bacterial cells, which 
permits genetic altered cells to grow and divide in the presence of antibiotic 
concentrations that would normally kill or inhibit unaltered cells. Antibiotic 
resistance from a clinical perspective is related to the drug concentration 
tolerance and pharmacokinetics of the patient and the effects on the bacteria 
at this concentration [42,43].  
 
Bacterial cells can alter their genome by acquiring plasmids (such as the 
CTX-M-15 plasmid disseminated in Enterobacteriaceae species [17]); by 
acquiring novel genomic material via viral vector (such as phages within the 
microbiome [44]) and by de-novo mutations (such as mutations observed in 
cystic fibrosis patients chronically infected with P. aeruginosa [45–47]). 
Despite the origins of the genomic antibiotic resistance adaptions, bacterial 
cells use four different types of antibiotic resistance mechanisms to evade 
drug effects. These mechanisms are: induction of multi-drug resistance 
(MDR) efflux pumps that expel the antibiotic drug from inside the cell; mod-
ification of the drug-target that prevent drug-target complexes forming; 
membrane modification that reduce permeability of the drug in to the cell; 
and production of enzymes that degrade the drug (Fig 4).  
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Fig 4. An overview mechanism of cellular resistance (on the left) and ac-
quisition of antibiotic genomic resistance (on the right) 
 
Examples of most of these molecular antibiotic resistance mechanisms are 
present within the two manuscripts presented at the end of this PhD thesis.  
For instance, in manuscript I there was induction of the acrAB-TolC efflux 
pump up-regulated in drug adapted bacterial populations by genomic modi-
fications in the acrR, marR, rob and soxR genes. In manuscript II there was 
mutations that conferred up-regulation of the mexXY-oprM efflux pumps by 
genomic modifications in the mexS, mexT and mexZ genes. Whereas there 
was reduced permeability of drug in manuscript I, where mutations in the 
cpxA and sbmA genes confer AMK resistance. In both manuscripts it was 
shown mutations that confer molecular antibiotic resistance by drug-target 
modifications. In manuscript I these mutation were observed in gyrA and 
fusA, and in manuscript II these were ftsI, gyrA, gyrB, parC, ftsI, rpoB. 
 
Usually most mutational antibiotic resistance variants come at a cellular 
fitness cost, due to the modification of essential cellular components. There-
fore it has been assumed that if there was no antibiotic selection, antibiotic 
resistant variants would disappear [48]. Selection of resistant mutants can 
nonetheless occur at exceptionally low antibiotic concentrations, as demon-
strated in the competition experiments performed by Gullberg et al. 2011. It 
is also important to state that some mutations to antibiotic agents come at 
little to no fitness cost and can easily be maintained within a population with 
no selection. Although most mutations do come at a fitness cost, these bacte-
rial cells undergo further evolution to develop compensation mutations that 
restore fitness [49]. An example of this is demonstrated in Markusson et al 
2009 work. Consequently, if sufficient time has allowed for bacteria to de-
velop both antibiotic resistance mutations and compensation mutations, then 
simply eliminating the use of antibiotics will not rectify the situation. Hence, 
systematic approaches to understanding antibiotic resistance development 
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and methods to exploit it in antibiotic treatment are essential and will be 
discussed in the chapter application of profiling drug resistance.  
 
From either a bacteriologist or clinical perspective, the best measurement of 
antibiotic resistance is using Minimal Inhibitory Concentration (MIC).  MIC 
values by antimicrobial susceptible testing are required to deem if a bacterial 
species or sample is susceptible (S) (where treatment is likely to be success-
ful), intermediate (I) (where its unknown if treatment will be successful) or 
resistant (R) (where treatment is unlikely to be successful to a given antibi-
otic) [50]. This will be covered in more detail in the next chapter on profiling 
drug resistance.  
Impacts and dissemination of Antibiotic Resistance 
The impacts of antibiotic resistance are considerable due to the fact that we 
are all possible stakeholders in requirement for antibacterial therapy (e.g. 
economically due to the cost of health care and for most medical treatment 
[51]). Many modern medical procedures rely on the use of antibiotics (e.g. 
prophylaxis and post-operative care for surgery [52], treatment for immuno-
comprised individuals [53] and treatment of sexually transmitted diseases 
[54]). There is a clear correlation that the more antibiotics we use the more 
bacterial antibiotic resistance occurs due to the large selective pressure we 
induce [55]. It is also important to state that there has always been a natural 
reservoir of antibiotic resistance that has existed before antibiotic usage. For 
instance, putative antibiotic resistance genes have been detected in ancient 
DNA studies (e.g. permafrost cores [56]) and the gut microbiome of 11th 
century pre-Columbian Andean mummy [57]). However, our misuse and 
over use will act as a strong selection to further disseminate antibiotic re-
sistance and cause further antibiotic resistance evolution. This is especially 
so if the selection pressure is strong enough, such those encountered during 
human or animal antibiotic treatment [58], effluent from manufacturing 
plants [59] or wastewater treatment plants [60]. Therefore, to prevent or limit 
antibiotic resistance it is important for academics, clinical and industry to 
work together in developing new antimicrobials, optimizing treatment strat-
egies and finding ways to minimize antibiotic usage to impede future antibi-
otic resistance. 
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Profiling and exploring drug treatment and 
resistance  
Profiling drug resistance mainly relies on categorizing different isolates from 
different samples on their drug concentration abilities. Isolates can be col-
lected from clinical samples, environmental samples and in-vitro adaptation 
experiments. The future of profiling drug resistance will also rely on mo-
lecular techniques on bacterial populations to provide a more comprehensive 
profiling of drug resistance. These methods will be elaborated on in this 
chapter. 
Phenotypic quantification of antibiotic resistance 
As mentioned in the previous chapter the best initial form of categorizing 
antibiotic resistance is by the drug’s in-vitro MIC value, which allows the 
strain’s antibiotic susceptible type be known. This can be measured either by 
broth dilution in incremental concentration steps or by epsilometer (E-test) 
assay. To perform these tests effectively, guidelines should be strictly ad-
hered to [61]. This is to ensure the only variable of the assay is antibiotic 
drug concentration. Once a MIC value has been obtained following the clini-
cal breakpoints on EUCAST website in accordance to the bacterial species 
[62], an antimicrobial susceptible type can be stated which can be S, I or R. 
The EUCAST clinical break-points have been determined by epidemiologi-
cal studies of a large number of bacterial isolates and are regularly updated 
and can be viewed on method (MIC or disk diffusion), antimicrobial and 
species (EUCAST Antimicrobial wild type distribution of microorganism). 
However, these guidelines are often slightly relaxed in research facilities, 
where MIC is often translated into antibiotic inhibitory concentrations (IC) 
at different population levels such as IC90 and IC50 values [63–65].  
 
Phenotypic quantification of two or more antibiotic drug agents can also be 
assessed. To evaluate this the fractional inhibitory concentration (FIC) can 
be measured following the checkerboard FIC methods [66], where agents are 
tested alone and together. From this an FIC index value can be calculated. 
Antibiotic combinational effects can be categorized as synergistic (more 
effective when used together), additive (the same effective when used to-
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gether, equivalent to using a double dose) and antagonistic (less effective 
when used together) [67].  
 
Further phenotypic evaluation of an adapting bacterial population can be 
performed by assessing the evolution of an antibiotic drug-pair compared to 
its single drug components. This is calculated by using the formula presented 
in Munck et al 2014 work, which relies on IC90 values of the drug-pairs and 
the single drug components before and after adaptation. From the calculated 
evolvability value, if a value ≥ 1 this implies that resistance to the drug-pair 
evolves to the same extent as the single drug components, whilst a evolvabil-
ity value of ≤ 1 implies that resistance to the drug-pair evolves to the lesser 
extent than the single drug components. This calculation helps to provide 
information that can indicate drug cross-resistance or more importantly col-
lateral sensitivity, a term that will be explained in the next chapter. For man-
uscript I the cryopreserved samples were obtain from Munck et al. 2014 
work on phenotypic assessment on evolved bacterial populations drug-pair 
and single drug, where we further evaluated the populations by using molec-
ular techniques.  
Molecular quantification of antibiotic resistance 
Molecular methods can reveal ‘omics’ changes (i.e. genomic, transcriptomic 
and proteomic changes) to bacterial isolates or populations depending on the 
procedure and method used. These methods can provide rapid and sensitive 
determination of antibiotic resistance from a wide range of samples.  
 
The simplest method is PCR, where DNA from an isolate or a sample can be 
amplified with designed primers to see whether a resistance gene is present 
or not. An advance of this method is quantitative PCR (qPCR), where moni-
toring the amplification of the PCR product can verify the presence of given 
genes and their amount in the sample. The qPCR is seen as an attractive 
diagnostic tool as it is rapid, accurate and sensitive compared to cultivation 
based determination and can provide information in epidemiological route of 
transmission etc. PCR methods have been used to determine tetracycline 
resistance genes [68], methicillin resistance encoded mecA gene in Staphylo-
cocci and rifampicin resistance in Mycobacterium tuberculosis [69] and 
plasmid mediated ampC in Gram negative species [70]. However, there are 
two main limitations to these PCR approaches. The first limitation being that 
the presence of these antibiotic resistance genes does not mean that treatment 
of certain antibiotics will fail, due to the expression of these genes being 
low; and the second limitation being that novel molecular mechanism can 
easily be missed [69].  
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The first problem can be overcome by using transcriptomic or proteomic 
methods; where with transcriptomics direct gene expression can be analyzed, 
and with proteomics protein levels and modification can be evaluated. Over-
coming the second problem requires a more in-depth analysis, such as using 
sanger sequencing and whole genome sequencing (WGS) on bacterial iso-
lates to capture the novel mutations. This can easily be performed but is ex-
pensive. These sequencing methods are frequently used for clinical isolates, 
adaptation laboratory evolution studies, and environmental samples. Other 
approaches can be taken such as metagenomics where sequencing the DNA 
of the whole community can take occur. This allows for detection of the 
whole resistome, but is limited on the annotated antibiotic resistance genes 
in public gene databases [71]. Another limitation to this technique is that 
most metagenomic methods rely on NGS platforms that generate short se-
quencing reads which can make assembly of genomes into long contigs hard 
with limited mapping resolution. But unlike other methods it does allow for 
the whole uncultured community to be sequenced. 
 
Therefore, our approach was in manuscript I to PCR amplify loci of interest 
in known antibiotic resistance genes and for manuscript II PCR amplify well 
known antibiotic resistance genes of interested and then use population se-
quencing on the MiSeq platform. We were fortunate that we only wanted to 
know the molecular resistance changes to our organism of interest that we 
could easily map to a reference. This allowed for us to generate amplicons to 
eliminate background noise, sequencing reads that were easy to map and 
directly detected variant and establish their frequency in the population. 
Verification of molecular detection of antibiotic 
resistance 
Unlike phenotypic assays, NGS data sets require validation of variants de-
tected as these are mere observations. This can be done by two different 
approaches: using gene editing tools or literature mining to find validation 
results.  In the first approach, modifications in an ancestral wild type are 
done by recombineering techniques such as homologous recombineering 
where SNPs and INDELS can be reintroduce [72], or by high-throughput 
SNP CRISPER-Cas9 technologies [73]. The second approach is the simpler 
of the two where validations have been previously been preformed, analyzed 
and values reported. 
 
In manuscript I selected mutations were recombineered, and relative fitness 
to the ancestral wild type, IC90 to a given drug and persistence at different 
drug concentrations was reported. For manuscript II all treatment enriched 
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non-synonymous mutations were in the literature mined, those where re-
combineering and MIC difference were reported are complied in table 4. 
Generation of clinical and environmental sample 
collections 
Most bacterial collections comprise of isolates from samples where microbi-
ology laboratories have processed the samples. Examples of these are P. 
aeruginosa isolate collection from sputum samples from cystic fibrosis pa-
tients [74,75] Staphylococcus aureus isolates from a teaching hospital [76]. 
However, especially in environmental samples, it is well known that only a 
small percentage of bacterial species can be isolated. Therefore many sample 
collections comprise of extracted DNA, which can later be analyzed by met-
agenomic techniques (e.g. pyrosequencing of antibiotic resistance-
contaminated river sediments [77]). In manuscript II we used culture-
independent methods to analyze our P. aerugionsa populations by extracting 
the DNA, amplifying our genes of interest and sequencing on the Miseq 
NGS platform. Validation of results was done with literature mining. 
Generation of laboratory generated sample collection 
To generate antibiotic resistance, sample collections tend to rely on adapta-
tion evolution experiments to evolve isogenic naïve wild types to become 
drug resistant. Unlike clinical bacterial isolate, where evolutionary changes 
lead to antibiotic resistance, adaptation evolution experiments allow to regu-
larly freeze samples to form cryopreserved stocks [78]. As the experiments 
are performed in controlled laboratory settings, scientific analysis of evolu-
tionary phenomena are easier to analyze [79]. Therefore, in turn, replay ex-
periments and tracking experiments can easily be performed.  
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Adaptation evolution experiments can be performed by two protocol ap-
proaches: a chemostat approach or a serial dilution protocol (Fig 5).  
 
Fig 5. An overview of adaptive evolution protocols: (A) Chemostat laborato-
ry set-up where a computer control optimizes the growth of the bacteria in 
the reaction vessel by continuously monitoring the OD and dynamically 
adjusting antibiotics concentrations; (B) Serial laboratory set-up where bac-
teria are grown in a microtire plate with increasing antibiotic concentration 
from left to right and bacterial replicated in different rows, by serial passag-
ing bacteria can adapt to higher levels of antibiotic (right).  
 
In the chemostat approach, bacterial populations are continuously exponen-
tially grown by the constant nutrients given and waste and excess bacteria 
removed. An example is the development of the ‘mobidostat’ explained in 
Toprak et al 2013 work, where bacterial populations are constantly measured 
for optical density to measure growth rate and antibiotic drugs can be dy-
namically administered. This device was used to generate in parallel E. coli 
adapted populations to three drugs (chloramphenicol, doxycline and trime-
throprim) for 20 days. From this study the analysis of evolutionary trajecto-
ries and end-point isolates were sequenced. Additionally, they also se-
quenced multiple time-points to understand the cumulative mutational de-
velopment in the dihydrofolate reductase gene. A similar process which we 
used in the generation of manuscript I. The chemostat approach best simu-
lates infections occurring within tissue or an organ where no transfer occurs 
[78]. The serial dilution approach of adapting bacterial populations grows 
bacteria for a given time period and then a small inoculum is transferred to a 
new vessel or well in increasing antibiotic concentration increments. An 
example is Munck et al. 2014 work, where in microtitre plates the wells that 
had the highest antibiotic concentration after incubation for 20 hours with an 
OD 600> 0.25 absorbance were re-inoculated at 1:40 dilution factor into fresh 
microtitre plates. This was done for 14 days. At the end of the experiment, 
bacterial populations from each drug condition and lineage had a representa-
tive isolate whole genome sequenced. This approach best simulates patient 
to patient transfer events [78].  
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Another alternative method for systematically examining antibiotic re-
sistance is to use strain collections consisting of genetic mutants. Examples 
are the use of the KEIO strain collection where systematically studying the 
intrinsic resistome of E. coli to various drugs and examining the phenotypic 
response yielded important results [80,81]. This has also been applied to P. 
aeruginosa by using transposon generated libraries, which then can be tested 
in a similar manner to examine the intrinsic resistome[82–84].  
 
In relation to the research work performed, in manuscript I genomic evalua-
tion of the cryopreserved population samples was generated by serial dilu-
tion adaption evolution experiments. Whilst in manuscript II, if to be re-
performed under strict laboratory conditions, a chemostat laboratory set up 
would probably be more applicable, due to the bacteria’s permeant residence 
in the cystic fibrosis patient lung. 
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Applications of profiling drug treatment and 
resistance landscapes 
The implication of profiling evolutionary landscapes in regards to antibiotic 
resistance are vital, for the ability to use antibiotic as an essential medical 
resource. Clinical antibiotic resistance is unfortunately not hard for bacteria 
to achieve due to the micro-niches in the body e.g. in the lungs, epidermis 
and joints [85]. Especially in these micro-niches bacteria experience sub-
inhibitory antibiotic concentrations, which impede but not prevent growth 
[85,86] and even allow evolution to occur to circumvent any negative ef-
fects. Therefore, through this next chapter I will discuss the application of 
profiling drug resistance landscapes.  
Traditional approaches to applying drug profiling for 
treatment, with limited antibiotic resistance outcomes 
Within microbiology it has been naively accepted that the development of 
bacterial antibiotic resistance can be impeded by the use of drug combina-
tions, especially those that exhibit synergistic effects. The assumption was 
that bacteria developing resistance to one drug was more likely than devel-
oping resistance to two drugs simultaneously [87]. Traditionally in the clini-
cal setting most antibiotic drug combinations are chosen due to their differ-
ent cellular targets [88], but despite many antibiotics attacking different cel-
lular targets bacteria often evolve the same mechanisms to resistant antibiot-
ics. These mechanisms are commonly known as cross-resistance 
mechanisms (e.g. are the multi-drug resistant efflux pumps and modifica-
tions to pleiotropic genes [89]). However, there are exceptions; e.g. it has 
been frequently found by in-vitro assays that many classes of antibiotics 
have synergy with aminoglycosides [90–92]. This did have great clinical 
success and now with understanding the molecular mechanisms we can elu-
cidate ways to utilize antibiotics more effectively. In the next sub-chapter, I 
will further explain the mechanisms of why aminoglycosides exhibit syner-
gistic qualities with other antibiotic drug classes. 
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Novel methods to systematically review drug reactions 
Traditional microbiology could only assess antibiotic resistance by pheno-
typic assays or by low throughput sanger sequencing to reveal genomic 
changes. With developments in molecular and automation technologies it is 
easier to study phenotypic drug responses and study cellular molecular 
changes. These new methods have been able to resurrect old hypothesis, 
such as collateral sensitivity, test them and provide important information to 
ascertain the application validity.  
 
Systematic studies can explore a bacterial species’ reaction to large volume 
of antibiotics. This can be done by investigating bacterial collections of gene 
knockouts, transposon mutant libraries, adaptation populations and endpoint 
isolates, and clinical or environmental isolate collections. Most studies have 
focused on WGS and reported where genomic resistance has occurred. This 
could provide critical intrinsic antibiotic resistance information (e.g. the 
dihydrofolate reductase gene in trimethoprim resistance [93]). Other studies 
have lead in promoting antibiotic treatment ideas and strategies, which hope-
fully can be used in clinical application once certain parameters have been 
satisfied.  
 
Ideas promoting novel targets were generated following the development of 
the Keio collection of approximately 4000 single gene knockouts. This al-
lowed scientists to test the Keio collection with different antibiotics. The 
first study by Tamae et al 2008 showed that with high-throughput screening 
of 7 drugs, there were genes that made a given bacterial strain hypersensi-
tivity to a given drug. This was further extended in Lui et al 2010 work with 
22 additional antibiotics. Both studies showed the complexity of the intrinsic 
resistome, and especially by targeting pleiotropic genes by co-drugs or anti-
biotic adjuvants, there was renewed hope in antibiotic treatments. Transpos-
on libraries in P. aeruginosa also have shown promise in exploiting intrinsic 
resistome weak-points that could be useful for co-drugs or antibiotic adju-
vants [82–84]. This produced the revival of an old idea of collateral sensi-
tivity [94]. In this work bacteria that were made resistant to a given antibi-
otic agent became more sensitive to another. This phenomenon was the main 
focus in Imamovic and Sommer 2013 work. By adapting E. coli bacterial 
populations to 23 antibiotics and evaluating drug susceptibility profiles, col-
lateral sensitivity and cross-resistance drug networks were established. After 
finding drug pairs that exhibited collateral sensitivity, a demonstration of 
drug cycling with gentamycin and cefuroxime was shown to be successful. 
Adaptation to each of the drugs was done sequentially and MICs of both 
drugs performed; the drug that was used for adaptation showed increased 
resistance whilst the other drug had a severely decreased MIC value. The use 
of drug networks displaying collateral sensitivity has also been explored by 
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Lazar et al. 2014, combining in-vitro adaptation of E. coli and whole genome 
sequencing to 12 antibiotic drugs with 5-6 replicates. It was later elucidated 
that aminoglycoside mutants often change key components required for en-
ergy production and permeability, whereas other resistance mutants e.g. 
chloramphenicol mutants require a higher demand of energy, e.g. mutants 
that up-regulate MDR efflux pumps. Using a similar approach, in Munck et 
al. 2014 work the experiment was performed on 10 drug-pairs and 5 single 
drugs done in triplicate for 14 days, showing that the drug pairs which in-
volve amikacin and another antibiotic agent such as chloramphenicol can 
limit the development of antibiotic resistance.  
 
To further elucidate these findings within the adaptive bacterial populations I 
used amplicon deep sequencing of around Munck et al 2014 end-point muta-
tions. From this we discovered that the collateral sensitive drug pair AMK-
CHL still developed resistance mutations in acrAB-TolC multi-drug resistant 
efflux transcriptional repressor genes, but did not develop mutations in the 
fusA and sbmA genes that is typical for AMK resistance development. These 
studies reported the genomic trade-offs that bacteria must make to become 
resistant to a given antibiotic drug, but this could leave them more vulnera-
ble to another type of antibiotic drug. Therefore, using collateral sensitive 
drug cycling networks and collateral sensitive pairs tools could be effective 
to increase the longevity of antibiotic therapy until new agents are available 
[95].  
Transfer in-vitro drug profiling results into possible 
clinical application 
To transfer these in-vitro findings from the laboratory to clinical practice, an 
expansion of data must occur regarding the use of different clinically rele-
vant pathogens and isolates [95]. Another consideration is antibiotic’s phar-
macodynamics parameters (that describe the impact of an antimicrobial 
agent on the target organism) and the pharmacokinetic parameters (that de-
scribe the availability of an antimicrobial agent in the target organ or tissue), 
which will provide information regarding the plausibility of using these 
agents within the patients [43]. It would be of interest to look into the long 
term effects of using antibiotic collateral sensitive treatment as a tool for 
possibly treating chronic infections, such as chronic pseudomonas infections. 
However today little is known of the bacterial population genomic diver-
gence of antibiotic resistant variants especially in individuals inflicted with 
chronic infections. In manuscript II we begin to look into this by studying 19 
genes in cystic fibrosis patients that have chronic p. aeruginosa lung infec-
tions whilst undergoing hospitalized treatment. We could see a vast array of 
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genomic mutant sub-populations present in the sputum samples. Therefore, 
understanding bacterial population divergence, sub-populations and the uses 
of different antibiotic and their deployment could help towards the treatment 
of bacterial pathogens. 
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Chapter 5. Concluding remarks and future 
perspectives  
As stated through out this PhD thesis, bacteria have many advantageous 
traits that allow them to evolve to a vast array of environmental conditions.  
These traits are their: short generation time, large population capabilities and 
their rate of spontaneous mutations. By following adaptive evolution of bac-
teria, we can observe evolution in real time [96] and freeze regular samples 
for later tracking genomic events as seen with in the two manuscripts of this 
PhD.   
 
The bacterial evolution studies within this PhD thesis are all related to intrin-
sic antibiotic resistance, within bacterial populations. Our molecular pipe-
lines could detect SNP and INDEL variants but not clearly detect gene du-
plication events.  
 
In manuscript I, deep amplicon sequencing of antibiotic loci were tracked 
over time to establish genomic events occurring in adapted collateral sensi-
tive drug-pair bacterial populations, in adapted collateral resistant drug-pair 
bacterial populations and in adapted single drug bacterial populations. Our 
finding from this research indicated that adapted collateral sensitive drug-
pair populations e.g. populations adapted to AMK-CHL stopped developing 
fusA and sbmA mutants but continue to develop mutants in other gene loci. 
In the adapted collateral resistance drug-pair these finding did not occur.  
Consequently, by using antibiotic collaterally sensitive drug pairs, evolution 
of antibiotic resistance can be limited but not completely inhibited it.   We 
also observe how mutational variants appear in the population and how their 
dynamics follow the rules describe by others such as clonal interference, 
population fixation, and periodic selection occur [34,35,97,98].  
 
Whilst in manuscript II, 19 P. aerugiosa antibiotic resistance and pathoga-
daptive whole genes were sequenced and analyzed from DNA extracted 
from chronically infected cystic fibrosis patients undergoing hospitalized 
antimicrobial therapy. The results of this manuscript indicated that there was 
a vast array of genomic variants produced during antimicrobial treatment; 
most of these were synonymous mutations. Therefore, we thought there 
could be environmental factors such as quorum sensing mechanisms endog-
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enous to P. aerugiosa [99] inducing genomic divergence or the use of the 
antibiotics themselves that could be inducing genomic divergence by mech-
anisms such as SOS response[100]. We then examined the non-synonomous 
mutations within the population and observed effects of clonal interference 
that has been well documented through literature by adaptation experiments 
in other Gram negative species [98,101].  These events are probably im-
portant for the development of antibiotic resistance within the bacterial pop-
ulations to find mutations are effective against antimicrobials that compro-
mise fitness the least. Most of our novel enriched variants were not described 
within the current scientific literature, with the exception of 11 variants, 
where three had follow up studies where the MIC increase reported. 
 
These studies have generated important but limited information. As men-
tioned by Hancock 2014, an expansion in antibiotic resistance information is 
required in different bacterial species, to several antibiotics and treatments, 
from different bacterial population locations.  
 
From the work here I hope I can expand in the future by developing larger 
data-sets regarding antibiotic resistance within bacterial populations, by ana-
lyzing data from both systematic in-vitro experiments and clinical samples. 
As well as developing sequencing pipelines to capture genomic events 
across the whole genome within bacterial species populations, so duplication 
events could also be captured.  
 
Maybe it is an ambitious statement to finish on, but by understanding factors 
that induce genomic variation we can hopefully find the mechanisms to im-
pede it, such as the quasi-Lamarckian mechanisms that induce neo-
Darwinism evolution in antibiotic resistance. Then using co-drug or antibi-
otic adjuvants [81,84,102,103] that target these quasi-Lamarckian mecha-
nisms, suppression of antibiotic resistance development can ensure the lon-
gevity of modern medical treatments. 
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Abstract 12 
Understanding	the	evolutionary	processes	leading	to	antibiotic	resistance	can	help	13 to	 achieve	 better	 treatment	 strategies.	 Genomic	 characterization	 of	 antimicrobial	14 adaptation	evolution	experiments	is	commonly	done	by	sequencing	representative	15 isolates	 from	end-point	 adapted	populations.	 Consequently,	 little	 is	 known	about	16 the	dynamics	of	 the	 resistance	alleles	during	adaptation.	Here	we	use	population	17 sequencing	to	monitor	genetic	changes	in	key	adaptive	loci	at	several	time-points	18 during	an	adaptive	evolution	experiment	to	five	different	antibiotic	conditions.	We	19 monitor	the	mutational	spectrum	in	putative	resistance	alleles	in	lineages	evolved	20 to	 single	 antibiotics	 (amikacin,	 chloramphenicol	 and	 ciprofloxacin)	 as	 well	 as	21 antibiotic	 combinations	 (amikacin	 +	 chloramphenicol	 and	 chloramphenicol	 +	22 ciprofloxacin).	 We	 find	 that	 lineages	 evolved	 to	 antibiotic	 combinations	 exhibit	23 
 
 
different	dynamic	resistance	adaptation	profiles	compared	to	single	drug	evolved	24 lineages.	 Analysis	 of	 allele	 frequency	 dynamics	 indicates	 interactions	 between	25 specific	mutations.	We	termed	these	clonal	interference	allelic	interactions,	super-26 imposing	 allelic	 interactions	 and	 population	 allelic	 fixation	 events.	 To	 assess	 our	27 observations	a	sub-set	of	mutations	were	introduced	into	the	ancestral	wild	type.	28 The	 resulting	 stains	were	 assessed	on	 relative	 fitness,	 IC90	 fold	 change	 from	 the	29 ancestral	wild	type	and	mutant	allelic	persistence	abilities.		30 
	31 
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Introduction 40 
Bacteria	have	an	impressive	ability	to	adapt	to	changes	in	their	environment.	Their	41 large	population	sizes	and	short	generation	times	allow	them	to	rapidly	evolve	and	42 adapt	 in	 response	 to	 environmental	 perturbations.	 In	 addition,	 their	 ability	 to	43 horizontally	 acquire	 new	 genetic	 material	 enables	 them	 to	 quickly	 expand	 their	44 functional	 capabilities.	 Consequently,	 bacteria	 have	 evolved	 to	 overcome	 stress	45 from	a	wide	range	of	xenobiotic	 including	disinfectants	(Gerba,	2015),	metal	 ions	46 (Sütterlin	et	al.,	2014)	and	antibiotics	(Dantas	and	Sommer,	2014;	Gullberg	et	al.,	47 2011;	Piddock,	2012;	Sommer	et	al.,	2010). 48 
In	the	case	of	more	severe	perturbations	such	as	high-level	antibiotic	exposure,	or	49 other	 xenobiotic	 perturbations	 the	 regulatory	 plasticity	 is	 not	 sufficient	 and	 the	50 bacteria	 have	 to	 evolve	 new	 traits	 to	 survive	 (Lindsey	 et	 al.,	 2013).	 This	 either	51 occurs	 via	 horizontal	 acquisition	 of	 new	 genes	 or	 through	mutations	 in	 existing	52 genes.	 In	 the	 latter	 case,	 random	 single	 nucleotide	 variants	 (SNVs)	 or	53 insertions/deletions	(INDELs)	in	the	genome	drive	the	evolution	of	new	traits.	The	54 ability	of	a	mutated	allele	to	establish	within	a	population	depends	on	the	complex	55 interplay	between	the	positive	selection	for	the	conferred	benefit	of	the	mutation	56 and	 negative	 selection	 against	 any	 associated	 fitness	 cost	 of	 the	 mutation.	 By	57 identifying	SNVs	and	INDELs	at	the	population	level	at	different	time	points	during	58 adaptation	 to	 a	 physical	 or	 chemical	 perturbation,	 it	 is	 possible	 to	 uncover	 the	59 trajectories	 through	 which	 a	 population	 evolves.	 Studies	 of	 such	 evolutionary	60 
 
 
trajectories	 have	 identified	 the	 mutational	 landscape	 that	 populations	 undergo	61 when	 adapting	 to	 different	 diverse	 perturbations	 such	 as;	 glucose	 as	 a	 limiting	62 nutrient	(Barrick	et	al.,	2009;	LaCroix	et	al.,	2015)	and	antibiotic	exposure	(Feng	et	63 al.,	2016;	Toprak	et	al.,	2011;	Zhang	et	al.,	2015). 64 
An	interesting	phenomenon	that	often	accompanies	the	mutational	responses	to	an	65 environmental	 perturbation	 is	 the	 emergence	 of	 collateral	 effects.	 This	66 phenomenon	 describes	 the	 situation	 where	 the	 adaptive	 mutations	 acquired	 in	67 response	to	one	perturbation	affect	the	cell's	tolerance	to	other	perturbations.	Such	68 collateral	effects	have	been	found	in	bacteria	(Imamovic	and	Sommer,	2013;	Lázár	69 et	 al.,	 2013;	 Munck	 et	 al.,	 2014;	 Oz	 et	 al.,	 2014;	 Pál	 et	 al.,	 2015;	 Szybalski	 and	70 Bryson,	1952),	viruses	(Miedema	et	al.,	2013)	and	human	cell	 lines	(Cerezo	et	al.,	71 2015;	Zhao	et	al.,	2016). 72 
Fundamentally,	 collateral	 changes	 can	 be	 divided	 into	 two	 categories;	 collateral	73 resistance	 and	 collateral	 sensitivity.	 Collateral	 resistance	 is	 the	 situation	 where	74 increased	tolerance	to	one	xenobiotic	perturbation	also	gives	 increased	tolerance	75 to	 other	 xenobiotic	 perturbations.	 In	 contrast,	 collateral	 sensitivity	 describes	 the	76 situation	 where	 increased	 tolerance	 to	 one	 perturbation	 is	 accompanied	 by	77 increased	sensitivity	to	other	perturbations.	In	a	recent	study	we	investigated	how	78 bacterial	 populations	 respond	 to	 a	 dual	 selection	 pressure	 relative	 to	 a	 single	79 selection	pressure	(Munck	et	al.,	2014).	Over	the	course	of	fourteen	days	bacterial	80 populations	were	adaptively	evolved	to	either	single	antibiotics	or	combinations	of	81 
 
 
two	 antibiotics.	 Interestingly,	we	 found	 that	 the	presence	 of	 collateral	 sensitivity	82 between	 two	 drugs	 significantly	 limited	 the	 populations'	 capacity	 to	 evolve	83 resistance.	 In	 the	 current	 study	we	 follow	 the	evolutionary	events	 at	 key	genetic	84 loci	in	bacterial	populations	that	have	been	exposed	to	increasing	concentrations	of	85 either	a	single	antibiotic	or	 	combinations	of	 two	antibiotics	(Munck	et	al.,	2014).	86 We	 investigated	 lineages	 evolved	 to	 amikacin	 [AMK],	 chloramphenicol	 [CHL],	87 ciprofloxacin	 [CIP],	amikacin	+	chloramphenicol	 [AMK-CHL]	and	chloramphenicol	88 +	 ciprofloxacin	 [CHL-CIP].	 The	 AMK-CHL	 drug	 combination	was	 selected	 since	 it	89 was	found	to	generate	evolutionary	tension	suppressing	evolution	of	antimicrobial	90 resistance,	 whereas	 the	 CHL-CIP	 combination	 was	 chosen	 since	 the	 component	91 drugs	 have	 complementary	 evolutionary	 trajectories	 that	 enhance	 resistance	92 evolution	towards	the	combination	(Figure	1A).	In	this	study	amplicon	population	93 sequencing	 and	 genome	 engineering	were	 used	 to	 characterize	 the	 evolutionary	94 dynamics	 in	 response	 to	 the	 individual	 antibiotics	 and	 antibiotic	 combinations	95 (Figure	1B).	96 
 97 
 98 
Materials	and	Methods 99 
Bacterial	Strains 100 
 
 
The	bacterial	strain	used	in	this	study	was	MG1655,	an	E.	coli	K-12	MG1655	wild-101 type	(Blattner	et	al.	1997)	for	the	adaptation	evolution	experiment	and	generation	102 of	 sample	 collection.	 Further	 characterization	 experiments	 were	 done	 on	103 successfully	recombined	strains	to	reintroduce	given	mutations,	 the	strains	were:	104 
E.	 coli	 K-12	 MG1655:marR	 C328T,	 E.	 coli	 K-12	 MG1655:rob	 G467A,	 E.	 coli	 K-12	105 MG1655:marR	C328T	+	rob	G467A,	E.	coli	K-12	MG1655:gyrA	A260G,	E.	coli	K-12	106 MG1655:	marR	T251A,	E.	 coli	K-12MG1655:gyrA	A260G	+	marR	T251A,	E.	 coli	K-107 12MG1655:soxR	 378_380delGCG	 and	 E.	 coli	 K-12MG1655:	 gyrA	 A260G	 +	 soxR	108 378_380delGCG. 109 
Sample	revival	and	DNA	extraction 110 
Saved	microtitre	plates	from	Munck	et	al	2014	were	defrosted	for	30	min	at	4°C,	to	111 prevent	 aerosol	 contamination	 plates	 were	 centrifuged	 at	 300g	 for	 5	 sec	 before	112 seal	 removal.	 To	 revive	 our	 samples,	 150μL	 samples	 were	 transferred	 to	 a	 new	113 tube	with	500μL	LB	media	 and	 incubated	at	37°C	 for	 three	hours.	Genomic	DNA	114 was	 extracted	 by	 using	 Genomic	 Mini	 kit	 in	 accordance	 to	 the	 protocol	 (A+A	115 biotechnologies). 116 
Resistance	allele	Primer	design 117 
The	 loci	 selected	 for	 sequencing	 were	 chosen	 based	 on	 knowledge	 of	 their	118 involvement	 in	 antibiotic	 resistance	 and	 the	 mutation	 profile	 in	 the	 end-point	119 sequenced	 original	 evolved	 lineages	 and	 population	 level	 loci	 sequencing	 was	120 
 
 
performed	on	day	2,	4,	6,	8,	10	and	10	(Figure	1A).	For	this	study	we	monitored	121 mutations	for	AMK:	cpxA,	fusA	and	sbmA;	for	CHL:	acrR,	marR,	rob	and	soxR;	for	CIP	122 
acrR,	gyrA	and	soxR;	for	AMK	+	CHL:	acrR,	cpxA,	fusA,	marR,	rob	and	soxR;	for	CHL	+	123 CIP:	 acrR,	 gyrA,	marR,	 rob,	 soxR.	We	 believe	 these	 loci	 cover	 important	 genomic	124 locations	to	begin	to	unravel	important	interaction	in	intrinsic	antibiotic	resistance.	125 Primers	were	designed	with	overhangs	to	allow	barcoding	with	Nextera	XT	indices	126 in	 accordance	 to	 Illumina	 16S	 Metagenomic	 Sequencing	 Protocol	 (Illumina	127 Protocol	Online)	to	amplify	12	different	genomic	regions	(Supplemental	Table	1)	128 in	 known	where	 resistance	 causing	 SNPs.	 All	 primers	were	 tested	 on	E.	 coli-K12	129 wild	 type	 genomic	 DNA	 and	 PCR	 products	 were	 verified	 by	 1%	 agarose	 gel	130 electrophoresis	with	GelRed	(Biotium). 131 
Amplicon	library	preparation	and	sequencing 132 
All	 samples	 were	 amplified	 using	 the	 primers	 in	 (Supplemental	 table	 1)	 and	133 following	 the	description	 in	 the	 above	 section	 for	 each	drug	 condition.	Each	PCR	134 reaction	was	done	in	0.2mL	sterile	PCR	tubes	and	consists	of	10L	phusion	flash	135 high-hidelity	PCR	master	mix	(ThermoFischer	Scientific),	0.5	M	forward	primer,	136 0.5	 	M	reverse	primer,	1	L	DNA	template	and	H20	to	a	total	reaction	volume	of	137 20	L.	 The	 PCR	 amplification	 used	 an	 initial	 denaturation	 of	 for	 98oC	 30	 s,	 30	138 cycles	consisting	of	a	98oC	for	10	s	denaturation,	65oC	for	10	s	annealing,	72oC	for	139 15	s	elongation,	72oC	final	extension	for	60	sec	then	hold	at	4oC.	To	validate	correct	140 
 
 
amplification	gel	electrophoresis	was	performed	with	1%	agarose	gel	and	stained	141 with	 ethidium	 bromide.	 After	 verification	 all	 the	 different	 loci	 amplicons	 that	142 belonged	to	the	same	drug-condition,	lineage	and	time-point	were	pooled	together.	143 PCR	products	were	cleaned	by	Agencourt	AMPure	XP	PCR	purification	system	used	144 according	 to	 their	online	protocol	 (Beckman	Coulter	2013).	The	barcoding	of	 the	145 amplicons	was	done	by	a	second	PCR	amplification	and	was	done	in	0.2mL	sterile	146 PCR	 tubes	 and	 consists	 of	 25L	 Phusion	 Flash	 High-Fiedelity	 PCR	 master	 mix	147 (ThermoFischer	Scientific),	5	 	L	Nextera	XT	 index	1	(N7XX),	5	M	Nextera	XT	148 index	 2	 (S5XX)	 (Illumina),	 5 	 L	 pooled	 amplicons	 and	 H20	 to	 a	 total	 reaction	149 volume	of	50	L.	The	PCR	amplification	used	an	initial	denaturation	of	for	98oC	30	150 s,	8	cycles	consisting	of	a	98oC	for	10	s	denaturation,	65oC	for	10	s	annealing,	72oC	151 for	15	s	elongation,	then	72oC	final	extension	for	60	sec	then	hold	at	4oC.	Barcoded	152 amplicons	 were	 cleaned	 according	 to	 Agencourt	 AMPure	 XP	 PCR	 purification	153 systems	 (Beckman	 Coulter	 2013).	 Barcoded	 amplicons	 were	 measured	 for	 DNA	154 concentration	 with	 Qubit	 dsDNA	 HS	 Assay	 kits	 and	 measured	 on	 Qubit	155 Fluorometer	(Thermo	Fischer	Scientific	Inc	2015)	and	average	fragment	size	with	156 Agilent	 DNA	 1000	 kit	 and	 measured	 on	 Agilent	 2100	 Bioanalyzer	 instrument	157 (Agilent	 Technologies	 2013).	 Then	 barcoded	 amplicons	 were	 pooled	 from	158 fragment	 size	 and	DNA	concentration	values	 to	 form	a	 sequencing	 library	based.	159 The	 sequencing	 library	 was	 sequenced	 on	 the	 MiSeq	 sequencing	 platform	160 (Illumina). 161 
 
 
Sequence	Analysis 162 
All	raw	sequencing	read	from	our	amplicon	sequencing	have	been	deposited	in	the	163 Sequence	 Read	 Archive	 (SRA)	 under	 bioproject	 accession	 PRJNA328094.	164 Sequencing	 reads	 were	 mapped	 to	 the	 reference	 genome	 (GenBank	 accession	165 NC_000913)	using	CLC	genomics	workbench	 (Qiagen).	These	 files	were	 exported	166 and	used	for	coverage	analysis.	To	verify	sequencing	coverage	mapping	read	files	167 from	CLC	genomic	workbench	and	using	 the	statistical	program	R	(R	Core	Team,	168 2014a).	Coverage	plots	were	generated	and	any	amplicons	than	were	below	our	set	169 threshold	of	1000	read	coverage	were	re-done	until	our	threshold	was	achieved,	to	170 ensure	 good	 quality	 data	 (Supplemental	 Figure	 1-5).	 To	 detect	 variants,	 all	171 mappings	were	 analyzed	with	 the	 basic	 variant	 detection	 calling	 function	 in	 CLC	172 genomic	workbench	(Qiagen).	Files	were	further	analyzed	using	the	program	R	(R	173 Core	Team,	2014b),	our	detected	variants	are	listed	in	Supplemental	Table	2. 174 
Recombineering	for	direct	mutagenesis 175 
For	 single	 mutant	 variants,	 the	 ancestral	 wild-type	 E.	 coli	 K-12	 MG1655	 was	176 transformed	 with	 the	 transient	 mutator	 plasmid	 PMA7sacB	 (GenBank	 accession	177 KT285941)(Lennen	 et	 al.,	 2016).	 For	 each	 single	 variant	 mutations	 two	178 recombineering	cycling	rounds	were	done	with	E.	coli	K-12	MG1655	harboring	the	179 PMA7sacB	 plasmid	 this	 was	 in	 accordance	 to	 the	MAGE	 cycling	with	 the	 single-180 stranded	 oligonucleotides	 (ss-oligo)	 with	 verification	 primers	 (Supplemental	181 
 
 
Table	3)	and	plasmid	curing	described	by	Lehnen	et	al.	2016.	Direct	mutagenesis	182 verification	was	confirmed	by	Sanger	sequencing,	done	with	Eurofins	Mix2Seq	kit	183 and	 following	 their	 instructions	 (Eurofins	 Genomics).	 After	 verification,	 double	184 mutant	 variants	 were	 created	 by	 taking	 one	 single	 mutant	 variants	 from	 the	185 observed	 double-mutant	 pair	 and	 transforming	 with	 the	 with	 the	 PMA7sacB	186 plasmid,	 recombineering	with	 the	other	mutant	variant	 ss-oligo	was	done	 in	 two	187 rounds	as	previously	described	and	plasmid	curing	was	also	performed.	 188 
Characterisation	of	recombineered	mutation	variant	strains 189 
Relative	growth	rate	as	 indictor	of	 fitness	was	done	for	all	recombineered	strains	190 and	 wild	 type.	 To	 measure	 relative	 growth	 fitness,	 overnight	 cultures	 in	 LB	191 medium	were	diluted	 to	1	x	106	CFU/mL,	 then	added	 to	96-well	microtitre	plate	192 with	 a	medium	 negative	 control	 all	 performed	with	 8	 biological	 replicates,	 with	193 two	technical	replicates	to	allow	calculation	of	the	relative	growth	rate.	Growth	of	194 the	samples	was	done	at	37oC	with	shaking	for	10s	and	kinetic	measurements	on	195 ELx808	 absorbance	 microplate	 reader	 with	 Gen5	 software	 (BioTek	 Instruments	196 Inc).	Optical	density	measurements	were	 taken	at	630	nm	 (OD630)	 every	10	min.	197 Exponential	growth	was	defined	as	OD630	values	between	0.02	and	0.1.	To	calculate	198 relative	 growth	R	 statistical	 software	was	used	 to	 find	 the	doubling	 time	 (Td)	of	199 each	of	 the	 strains	 and	 the	 standard	deviation	 (Td	SD),	 then	 to	 calculate	 relative	200 growth	 rate,	 the	 recombineered	 strain	Td	value	was	divided	by	 the	wild	 type	Td	201 value.	Selective	advantage	was	measured	by	performing	IC90	determination	assays	202 
 
 
to	 the	 antibiotic	 drug	 condition	 where	 the	 mutations	 were	 observed.	 IC90	203 determination	 was	 performed	 in	 96-well	 microtitre	 plates	 with	 2-fold	 drug	204 gradient	consisting	of	10	drug	concentrations	prepared	in	LB	broth,	each	well	had	a	205 volume	100  	L	and	was	inoculated	with	1	 	L	bacterial	culture	to	provide	well	206 start	 inoculum	1x10	 CFU/mL,	 each	 plate	 had	 8	 biological	 replicates.	 Plates	were	207 incubated	 for	 18h	 at	 37oC,	 and	 OD600	 was	 read	 on	 Synergy	 H1	 plate	 reader	208 (BioTek	Instruments	Inc). 209 
Results	 210 
Selection	of	alleles	for	population	sequencing. 211 
We	specifically	targeted	putative	resistance	alleles	identified	by	Munck	et	al.	2014	212 through	whole	genome	sequencing	of	evolved	 isolates.	As	 template	we	used	DNA	213 isolated	from	evolving	populations	sampled	every	48	hours	of	the	experiment.	The	214 following	 genomic	 loci	 (and	 drug	 conditions)	were	 studied:	 cpxA,	 fusA	 and	 sbmA	215 (AMK);	marR	 and	 rob	 (CHL);	acrR,	gyrA	 and	 soxR	 (CIP);	 cpxA	 and	marR	 (AMK	 +	216 CHL);	acrR,	marR,	gyrA	and	soxR	(CHL	+	CIP).	These	genes	are	implicated	in	either	217 multi-drug	resistance	(collateral	resistance)	or	specific-drug	resistance	(collateral	218 sensitivity).	 The	 genes	 implicated	 in	 multi-drug	 resistance	 include	 global	219 regulators	 that	 induce	up-regulation	of	 acrAB-TolC	multi-drug	 efflux	 systems,	 i.e.	220 
acrR,	 marR,	 rob	 and	 soxR	 (Chubiz	 et	 al.,	 2012a).	 Mutations	 in	 these	 global	221 regulators	 often	 have	 generalized	 cross	 resistance	 effects	 to	 many	 antibiotic	222 
 
 
classes.	Consequently,	we	termed	these	as	mutations	in	cross	resistance	gene	loci.	223 In	contrast,	genes	implicated	in	specific-drug	resistance	are	gyrA	mutations	(Fu	et	224 al.,	2013),	that	confer	CIP	resistance,	and	cpxA	(Girgis	et	al.,	2009),	fusA	(Johanson	225 and	Hughes,	1994)and	sbmA	(Chubiz	et	al.,	2012b;	Puckett	et	al.,	2012),	that	confer	226 AMK	resistance.		227 
Mutant	 allele	 dynamics	 differ	 between	 single	 drug	 and	 drug	228 
combination	evolved	populations 229 
Our	sample	collection	consisted	of	90	samples	from	15	bacterial	populations.	These	230 were	triplicates	of	adaptive	evolution	experiments	to	5	drug	conditions.	3	of	these	231 were	 single	 drugs:	 AMK,	 CHL,	 CIP;	 and	 2	were	 drug	 combinations:	 AMK-CIP	 and	232 CHL-CIP.	The	triplicate	parallel	 lineages	were	assigned	 letters	 from	A-C	and	were	233 sampled	on	6	time-points	(Day:	2,	4,	6,	8,	10	and	12)	(Figure	1A).	From	our	sample	234 collection,	we	extracted	genomic	DNA,	amplified	loci	of	interest,	verified	products	235 by	 gel	 electrophoresis,	 pooled	 together	 amplicons	 comprising	 targeted	 alleles	236 based	on	drug-condition	and	time-point,	barcoded	the	amplicons	with	indices	in	a	237 second	 PCR	 step,	 and	 pooled	 them	 together	 to	 form	 a	 sequencing	 library.	 The	238 library	 was	 then	 sequenced	 using	 the	 MiSeq	 sequencing	 platform	 to	 establish	239 mutational	population	 frequency	dynamics	 in	antibiotic	resistance	conferring	 loci	240 (Material	and	Methods	and	Figure	1B).	A	minimum	coverage	of	1000	sequencing	241 reads	 per	 amplicon	was	 required	 before	 further	 data	 processing	 (Supplemental	242 
Figure	1-5).		243 
 
 
From	our	 results	we	wanted	 to	 compare	 the	 allele	 frequency	 dynamics	 of	 single	244 drug	 evolved	 populations	 versus	 combination	 drug	 evolved	 populations.	 We	245 observed	differences	in	the	cumulative	frequencies	of	mutations	of	some	genes	in	246 the	combination	condition	compared	to	their	single	drug	components	(Figure	2A).		247 There	 were	 minor	 differences	 in	 gene	 loci	 mutational	 cumulative	 frequencies,	248 except	 for	 the	 collateral	 sensitive	 gene	 loci	 of	 AMK-CHL	 compared	 to	 AMK.	 It	 is	249 assumed,	 that	 antibiotic	 combinations	 would	 suppress	 antibiotic	 resistance	250 evolution	compared	to	drug	monotherapy.	Yet,	we	have	previously	shown	that	this	251 is	 not	 always	 the	 case;	 instead	 only	 combinations	 with	 collateral	 sensitivity	252 interactions	seem	to	suppress	drug	evolution	(Munck	et	al.,	2014).	We	did	a	Holm-253 Sidak	multi-comparison	two-way	ANOVA	statistical	test	to	compare	the	cumulative	254 mutational	frequencies	between	different	drug	conditions	and	sequenced	gene	loci	255 characterized	 in	 this	 study.	 We	 found	 spurious	 differences	 between	 single	 and	256 combination	 drug	 conditions	 in	 their	 respective	 cumulative	 mutational	257 frequencies.	 However,	 two	 gene	 loci	 showed	 consecutive	 significant	 differences	258 over	 two	 or	more	 time-points.	 These	were	 the	 fusA	 gene	 and	 sbmA	 gene,	where	259 mutations	were	 significantly	 less	 frequent	 in	AMK-CHL	drug	evolved	populations	260 compared	 to	 the	 AMK	 drug	 evolved	 populations	 (p-value	 ≤0.001,	 Holm-Sidak	261 multi-comparison	 two-way	 ANOVA	 test)	 (Figure	 2B).	 This	was	 also	 observed	 in	262 the	work	of	Munck	et	al	2014	and	likely	results	 from	collateral	sensitivity	to	CHL	263 caused	by	these	mutations	(de	Cristobal	et	al.,	2008;	Macvanin	et	al.,	2005).		264 
 
 
Populations	 exhibit	 complex	 dynamics	 of	 mutant	 alleles	 during	265 
antibiotic	resistance	evolution 266 
To	 elucidate	 important	 mutant	 alleles	 within	 our	 populations,	 we	 selected	 all	267 alleles	that	appeared	in	at	least	one	time-point	with	a	population	frequency	≥30%	268 (Supplemental	 Figure	 6).	 We	 observed	 5	 mutations	 that	 occurred	 in	 parallel	269 evolution	 events	 in	 different	 adapted	 populations	 (AMK:	 cpxA	 Trp184Arg,	 fusA	270 Pro610Gln;	AMK-CHL:	acrR	 Lys55Glu;	 CIP	 and	CHL-CIP:	gyrA	 Ser83del;	 CHL-CIP:	271 
soxR	Arg20Cys).	Out	of	these	mutations,	2	have	not	previously	been	reported	in	the	272 literature,	namely	acrR	Lys55Glu	in	AMK-CHL	populations	and	cpxA	Trp184Arg	in	273 AMK	populations.	We	speculate	that	the	acrR	Lys55Glu	mutation	confers	resistance	274 to	the	CHL	component	in	the	AMK-CHL	populations	by	up-regulation	of	the	acrAB-275 TolC	multi-drug	efflux	pump	whereas	cpxA	Trp184Arg	confers	AMK	resistance	by	276 modifying	membrane	stress	response.		277 
The	 most	 prevalent	 mutation	 in	 the	 evolved	 bacterial	 populations	 was	 gyrA	278 Ser83del,	as	 it	was	observed	 in	3	CHL-CIP	and	2	CIP	populations	at	several	 time-279 points.	The	gyrA	gene	often	mutates	at	amino	acid	position	83	however	it	has	only	280 been	reported	once	 that	 the	mutation	was	due	 to	a	deletion	of	 the	codon	(Jaktaji	281 and	Mohiti),	 as	 seen	 within	 our	 data.	We	 saw	 this	 mutation	 in	 high	 prevalence,	282 especially	in	the	CHL-CIP	lineage	A,	where	on	day	12	it	was	observed	at	a	frequency	283 of	100%	in	the	population.	However,	this	mutant	allele	was	not	detected	in	Munck	284 
 
 
et	 al	 2014	 work	 possibly	 due	 to	 the	 use	 of	 whole	 genome	 sequencing	 of	 a	285 representative	isolate	from	the	population.		286 
Within	 our	 data	 we	 observed	 three	 distinct	 accumulation	 patterns	 of	 different	287 mutant	 alleles	 (Figure	 3A).	 We	 termed	 these:	 discordant	 allele	 frequency	288 dynamics,	where	 the	mutant	alleles	have	opposing	 frequency	 trajectories	 to	each	289 other	 (Figure	 3A	 (i-iii));	 super-imposing	 allele	 frequency	 dynamics,	 where	 the	290 mutant	 alleles	 have	 the	 same	 frequency	 trajectories	 (Figure	 3B	 (i-iii));	 and	291 accumulating	 allele	 frequency	 dynamics,	 where	 one	 allele	 accumulates	 in	 the	292 population	following	the	accumulation	of	another	allele	(Figure	3C	(i-iii)).		293 
We	 observed	 discordant	 allele	 frequency	 dynamics	 in	 three	 populations:	 CIP	294 lineage	B,	 AMK	 lineage	B	 and	CHL	Lineage	 C.	 For	 CIP	 lineage	B	we	were	 able	 to	295 infer	direct	antagonistic	interactions	as	the	mutations	were	within	the	distance	of	a	296 single	read.	We	observed	that	the	individual	reads	only	had	an	amino	acid	change	297 in	 gyrA	 at	 position	 Ser83del	 or	 Asp87Gly	 for	 the	 time-points	 4	 to12.	 These	298 interference	 patterns	 could	 be	 a	 result	 of	 mutational	 incompatibility	 or	 clonal	299 interference,	 but	 further	 experimentation	 is	 required	 to	 deduce	 which	 effect	 is	300 responsible	for	our	observations.		301 
We	observed	super-imposing	allele	frequency	dynamics	in	three	populations:	AMK	302 Lineage	C,	CHL-CIP	lineage	A	and	CIP	lineage	A.	For	all	three	populations	the	two	303 mutant	 alleles	 have	 similar	 population	 frequency	 over	 multiple-time	 points	304 
 
 
(Figure	 3	 (C)	 (i-iii)).	 Such	 accumulation	 patterns	 likely	 result	 from	 the	 quick	305 succession	 of	 two	 separate	 mutations	 within	 a	 cell.	 Since,	 our	 population	306 sequencing	was	 performed	 only	 every	 48-hours	we	 have	 likely	 not	 been	 able	 to	307 resolve	occurrence	of	such	successive	events.			308 
For	 the	 accumulating	 allele	 frequency	 dynamics	 we	 observed	 one	 allele	 that	309 occurred	 at	 high	 frequency	 in	 the	 population	 followed	 by	 the	 accumulation	 of	 a	310 subsequent	 allele.	 This	 was	 observed	 in	 three	 populations:	 AMK	 lineage	 B,	 CHL	311 Lineage	 B	 and	 CIP	 Lineage	 A.	 These	 observations	 could	 be	 the	 result	 of	 two	312 possible	 effects,	 firstly	 the	hitchhiking	 effect	where	 a	neutral	mutant	 allele	 is	 co-313 occurs	with	a	beneficial	mutant	allele	due	to	 the	selective	advantage	provided	by	314 the	 beneficial	 allele	 the	 neutral	 mutation	 is	 therefore	 irreversible	 (Taddei	 et	 al.,	315 1997;	 Tenaillon	 et	 al.,	 1999)	 or	 secondly	 through	 positive	 or	 neutral	 epistasis	316 (Fogle	et	al.,	2008;	Sniegowski	et	al.,	1997).	Unlike	the	super-imposing	trajectories,	317 the	original	mutation	can	be	readily	identified.		318 
Recombineering	permits	validation	of	allelic	interactions	319 
To	follow	up	on	our	observations	we	used	recombineering	to	engineer	strains	with	320 our	observed	mutant	alleles.	This	was	done	with	a	sub-set	of	detected	mutations	321 exhibiting	super-imposing	or	discordant	accumulation	patterns.		By	measuring	the	322 relative	growth	rate	and	antibiotic	tolerance	of	the	isogenic	mutants	compared	to	323 the	 ancestral	wild	 type	we	were	 able	 to	deduce	why	 some	mutation	 interactions	324 occurred	(Figure	4A	(i-ii)).		325 
 
 
For	 our	 discordant	 mutational	 allelic	 frequency	 dynamic	 pair	 observed	 in	 CHL	326 lineage	C	population	we	observed	 that	 the	 rob	G467A	allele	became	dominant	 in	327 the	population	and	marR	C328T	was	lost	from	the	population	from	day	6	onward	328 (Figure	 3A	 (iii)).	 Therefore	 we	 recombineered	 3	 bacterial	 strains	 MG1655:rob	329 G467A,	 MG1655:	 marR	 C328T	 and	 MG1655:	marR	 C328T+rob	 and	 tested	 each	330 strain	for	relative	growth	rate	and	CHL	IC90	fold	increase	from	wild	type	(Figure	331 
4A	(i)).	From	our	recombineering	results	we	deduced	that	the	MG1655:rob	G467A	332 strain	was	selected	due	to	its	selective	advantage	to	the	antibiotic	perturbation	in	333 comparison	to	MG1655:	marR	C328T	strain	(Figure	4A	(i)).	As	the	recombineered	334 strain	MG1655:rob	G467A		had	IC90	fold	increase	of		6	from	the	ancestral	wild	type	335 compared	to	MG1655:	marR	C328T	strain	with	a	fold	increase	of	5.5.		Accordingly,	336 we	 hypothesize	 that	 the	 observed	 accumulation	 patterns	 in	 the	 CHL	 lineage	 C	337 population	result	 from	clonal	 interference	and	not	mutational	 incompatibility.	To	338 validate	this	assumption	we	recombineered	the	strain	MG1655:	marR	C328T+rob	339 G467A,	this	strain	was	viable	and	also	had	a	strong	CHL	tolerance	as	it	had	an	IC90	340 fold	 increase	of	 11	 compared	 to	 the	 ancestral	wild	 type.	However,	 the	 strain	did	341 have	 a	 reduced	 relative	 growth	 rate,	 in	 comparison	 to	 the	 single	 mutate	 allele	342 components	and	in	the	ancestral	wild	type.		343 
For	 our	 super-imposing	 mutations	 we	 tested	 our	 observation	 in	 the	 CHL-CIP	344 lineage	A	population,	where	gyrA	247_249delTCG	and	marR	T251A	appeared	at	the	345 same	 frequency	 from	 day	 8	 (Figure	 3B	 (ii)).	 Therefore	 we	 recombineered	 3	346 
 
 
bacterial	 strains	 MG1655:gyrA	 247_249delTCG	 MG1655:	 marR	 T251A	 and	347 MG1655:	gyrA	247_249delTCG+	marR	T251A	and	tested	each	engineered	strain	for	348 relative	 growth	 rate	 and	 CHL-CIP	 tolerance	 compared	 to	 the	 ancestral	wild	 type	349 (Figure	4A	(ii)).	350 
We	find	that	the	bacterial	cells	possessing	both	mutant	alleles	gyrA	247_249delTCG	351 and	marR	 T251A	 have	 a	 strong	 selective	 advantage,	 as	 the	 IC90	 of	 the	 double	352 mutant	was	11-fold	higher	than	the	ancestral	wild	type,	compared	to	4.3-fold	and	353 6.6-fold	for	the	single	mutants	gyrA	247_249delTCG	and	marR	T251A,	respectively.	354 The	double	mutant	did	have	a	reduced	relative	growth	rate	of	0.75	when	grown	in	355 antibiotic	 free	 conditions.	 We	 believe	 these	 mutations	 complement	 each	 other:	356 
gyrA	247_249delTCG	 confers	direct	 resistance	 against	CIP	 (Fu	et	 al.,	 2013)	while	357 
marR	 T251A	 induces	 up-regulation	 of	 the	 acrAB-TolC	 multi-drug	 efflux	 pump	358 causing	collateral	resistance	to	both	CHL	and	CIP	(Chubiz	et	al.,	2012a).		359 
Our	 previous	 observations	 coupled	 with	 our	 recombineering	 results	 show	 that	360 bacteria	sample	many	mutant	allele	types.	Mutant	alleles	that	are	disadvantageous	361 dissipate	 quickly	 from	 the	 bacterial	 population	 such	 as	 the	 three	 mutant	 allelic	362 losers	in	discordant	mutation	allelic	dynamics	(CIP	Lineage	B:	gyrA	Ser83del;	AMK	363 Lineage	B:	cpxA	Trp184Arg;	CHL	Lineage	C:	marR	Gln110*).	Whilst	those	that	aid	364 survival	 persist	 such	 as	 the	 interactions	 demonstrated	 in	 the	 super-imposing	 or	365 accumulating	mutational	allelic	dynamics	 (AMK	Lineage	B:	cpxA	Asp31Tyr	+	 fusA	366 Pro610Gln;	CHL	Lineage	B:	marR	Arg86Trp	+	rob	Arg150His;	CIP	Lineage	A:	gyrA	367 
 
 
Asp	87Tyr	+	gyrA	Gln75Ser;	CHL-CIP	Lineage	B:	gyrA	Ser83del	+	marR	Val	84Glu).	368 These	mutant	alleles	will	either	become	part	of	the	population’s	adaptation	history	369 or	will	be	eventually	lost	to	a	new	mutant	allele	successor.		370 
	371 
Discussion	372 
From	previous	work	by	Munck	et	al	2014	we	observed	mutations	that	counteract	373 the	 effects	 of	 antibiotics	 both	 by	 collateral	 resistance	 and	 collateral	 sensitive	374 mechanisms.	 The	Munck	 et	 al	 2014	 study,	 as	well	 as	many	others	 relies	 on	 end-375 point	 genome	 sequencing	 of	 representative	 isolates	 to	 investigate	 evolved	376 populations.	 In	 this	 study	we	 show	 the	 importance	 of	 using	 next	 generation	 re-377 sequencing	tools	to	further	evaluate	adaptation	evolution	in	mutated	loci	over	time		378 
at	the	population	level.	Using	this	approach,	we	find	that	selecting	drug-pairs	based	379 on	 collateral	 sensitivity	 can	 reduce	 or	 impede	 antibiotic	 resistance	 development.	380 Also,	 we	 show	 that	 longitudinal	 population	 sequencing	 can	 identify	 putative	381 epistatic	 effects	 (e.g.	 CIP	 Lineage	 B	 clonal	 interference	 in	 gyrA	 between	 mutant	382 alleles	Ser83del	and	Asp87Gly).	383 
Using	population	 amplicon	 sequencing	 allowed	us	 to	 discover	 several	mutations,	384 numerate	their	frequency	in	the	whole	populations	and	follow	their	frequency	over	385 the	experimental	time	course.	However,	we	are	unable	to	establish	any	subsidiary	386 antibiotic	mutations	outside	our	gene	loci	or	resolve	any	compensations	mutations.	387 
 
 
Nonetheless	we	believe	these	direct	approaches	will	play	a	critical	role	in	 in-vitro	388 adaptation	 evolution	 experiments	 and	 with	 methodology	 modification	 could	389 extend	to	population	sequencing	studies	 in-vivo.	This	will	be	 important	 in	several	390 cases	including	monitoring	of	chronic	conditions	that	require	long-term	antibiotic	391 treatment	 i.e.	 chronic	 urinary	 tract	 infections	 (Blango	 et	 al.,	 2014;	 Nolan	 et	 al.,	392 2015)	 or	 cystic	 fibrosis	 patients	 colonized	 with	 Pseudomonas	 aeruginosa	393 (Folkesson	 et	 al.,	 2012)	 and	 Staphylococcus	 aureus	 infections	 (Vanderhelst	 et	 al.,	394 2012).	395 
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Figure	Legends 559 
 560 
Figure	 1.	 	 Experimental	 overview	 of	 investigation	 from	 sample	 collection	561 
description,	 adaptation	 laboratory	 evolution	 (ALE)	 overview	 and	 amplicon	562 
frequency	work-flow.	(A)	Background	to	our	frozen	sample	condition,	showing	5	563 drug	 conditions	 (AMK,	 CHL,	 CIP,	 AMK-CHL	 and	 CHL-CIP)	 each	 with	 3	 lineages	564 (Lineages	 A,	 B,	 C)	 covering	 6	 time-points	 (Day	 0,	 2,	 4,	 6,	 8,10	 and	 12)	 from	 the	565 adaptation	 laboratory	experiments.	(B)The	workflow	used	to	assess	different	 loci	566 from	 different	 drug	 conditions,	 lineages	 and	 time-points,	 where	 (1)	 DNA	 was	567 extracted	from	the	different	sample,	(2)	each	sample	has	amplicons	for	each	locus	568 these	were	generated	by	primers	that	had	a	DNA	amplifying	region	and	an	Illumina	569 Nextera	XT	compatible	overhang,	(3)	these	were	then	barcoded	using	indices	from	570 the	Illumina	Nextera	XT	library	preparation	kit,	 (4)	all	generated	amplicons	were	571 pooled	together	based	on	fragment	size	and	concentration,	(5)	the	pooled	amplicon	572 
 
 
library	 was	 sequenced	 on	 MiSeq	 Illumina	 sequencing	 platform,	 (6)	 each	 sample	573 was	sorted	by	barcode	and	each	generated	a	 file	to	map	to	the	reference	genome	574 and	call	variants	in	the	bacterial	population	and	calculate	their	frequency.	 575 
 576 
Figure	2.	Comparative	cumulative	mutation	frequencies	of	gene	loci	for	each	577 
drug	condition	over	deep-sequencing	time-points	(A)	The	cumulative	mutation	578 frequency	calculated	for	each	time-point,	after	removal	of	all	mutations	below	5%	579 (i)		from	left	to	right	AMK	(showing	cpxA,	fusA	and	sbmA	gene	loci),	CHL	(showing	580 
acrR,	marR,	rob	and	soxR	gene	loci)	and	AMK-CHL	(showing	acrR,	cpxA,	fusA,	marR,	581 
rob,	sbmA	and	soxR	gene	loci),	(ii)		from	left	to	right	CHL	(showing	acrR,	marR,	rob	582 and	soxR	gene	loci),	CIP	(showing	acrR,	gyrA,	rob,	and	soxR	gene	loci)	and	CHL-CIP	583 (showing	 acrR,	 gyrA,	 marR,	 rob,	 and	 soxR	 gene	 loci).	 (B)	 Heat-map	 of	 showing	584 difference	 cumulative	 mutational	 frequencies	 for	 fusA	 and	 sbmA	 gene	 loci	 from	585 AMK	and	AMK-CHL	drug	 conditions	 at	 each	 time-point	 by	Holm-Sidak’s	multiple	586 comparison	two-way	ANOVA	between	(All	dark	grey	points	are	not	significant	and	587 all	blue	points	are	significant	with	a	P-value	below	0.0001). 588 
 589 
Figure	3.	 	Epistatic	mutation	 interaction	observation	on	the	whole	bacterial	590 
population.	 	 Epistatic	 mutation	 interaction	 observation	 on	 the	 whole	 bacterial	591 population	 with	 the	 three	 types	 of	 mutational	 interactions	 shown	 with	 three	592 examples	of	each	(A)	Discordant	mutational	allelic	interactions,	where	mutational	593 areas	form	different	fractions	of	the	population	either	red	fill	or	grey	fill,	from	left	594 
 
 
to	 right	 (i)	 CIP-Lineage	 B	 (with	 gyrA	 Asp87Gly	 in	 grey	 line	 and	 fill	 and	 gyrA	595 Ser83del	 in	 red	 line),	 (ii)	AMK-Lineage	B	 (with	 sbmA	Ala169Glu	 in	 grey	 line	 and	596 
cpxA	Trp184Arg	 in	 red	 line)	 and	 (iii)CHL-Lineage	C	 (with	 rob	Arg156His	 in	 grey	597 and	marR	Gln110*	in	red	line)	(B)	Super-imposing	mutational	allelic	 interactions,	598 where	 both	 mutations	 are	 present	 at	 the	 same	 time	 therefore	 the	 mutational	599 frequency	area	is	purple	fill	as	it	assumed	that	both	mutations	are	co-existing	in	the	600 bacterial	cells,	from	left	to	right,	(i)AMK	-Lineage	C	(with	cpxA	Ala79Val	in	grey	line	601 and	fusA	Ala608Val	red	line),	(ii)	CHL-CIP	Linage	A	(with	gyrA	Ser83del	in	grey	line	602 and	marR	Val84Glu	red	 line)	and	(iii)	CIP	Lineage	A	 	 (with	gyrA	Ser83del	 in	grey	603 line	 and	 soxR	 Ser126_Arg127delinsSer	 in	 red	 line)	 (C)	 Accumulating	 mutational	604 allelic	 interaction,	 where	 mutation	 arises	 the	 frequency	 area	 shown	 in	 grey	 fill,	605 then	the	second	mutation	arises	in	the	background	of	the	first	therefore	we	assume	606 that	 both	 are	 present	within	 the	 bacterial	 cells	 so	 purple	 frequency	 area	 fill	was	607 used,	 from	 left	 to	 right	 (i)AMK	–Lineage	B	 (with	 fusA	Pro610Gln	 in	grey	 line	and	608 
cpxA	Asp31Tyr	 in	 red	 line),	 (ii)	CHL	Linage	B	 (with	marR	 	Arg86Trp	 in	grey	 line	609 and	 rob	 Arg156His	 in	 red	 line)	 and	 (iii)	 CIP-	 Lineage	A	 (with	gyrA	 	 Asp87Tyr	 in	610 grey	line	and	gyrA	Gly75Ser	in	red	line).		611 	612 
Figure	 4.	 Evaluation	 of	 strains	 based	 on	 relative	 growth	 rate	 and	 IC90	 fold	613 
change	 from	 ancestral	 wild-type,	 where	 green	 on	 the	 plots	 represent	 ≥	 1	614 
relative	growth	rate	and	a	IC90	fold	change	from	wild	type	above	≥10	and	615 
red	≤0.5	relative	growth	rate	and	a	IC90	fold	change	from	wild	type	above	≤2.	616 
 
 
(A)	(i)	Recombineed	strains	to	assess	the	discordant	mutation	allelic	 interactions	617 based	 on	 mutation	 found	 in	 CHL-Lineage	 C	 (strains	 labelled	 accordingly	 on	 the	618 right	hand-side)	(ii)	Recombineered	strains	to	access	the	superimposing	mutation	619 allelic	interactions	based	on	mutation	found	in	CHL-CIP	Linage	A	(strains	labelled	620 accordingly	on	the	right	hand-side).	621 	622 
Supporting	Information	Legends	623 
	624 
SI	Table1.		Primers	for	generation	of	amplicons	625 
	626 
SI	Table	2.		Variant	detection	table	627 
	628 
SI	Table	3.		Homologous	recombineering	oligos	and	verification	primers 629 
	630 
SI	 Figure	 1.	 Coverage	 plots	 for	 each	 investigatory	 amplicon	 for	 AMK	 drug	631 
condition 632 	633 
SI	 Figure2.	 Coverage	 plots	 for	 each	 investigatory	 amplicon	 for	 CHL	 drug	634 
condition	635 
 636 
SI	 Figure3.	 Coverage	 plots	 for	 each	 investigatory	 amplicon	 for	 CIP	 drug	637 
condition 638 
 
 
	639 
SI	Figure	4.	Coverage	plots	for	each	investigatory	amplcion	for	AMK-CHL	drug	640 
condition	641 
	642 
SI	Figure	5.	Coverage	plots	for	each	investigatory	amplcion	for	CHL-CIP	drug	643 
condition	644 
SI	 Figure	 6.	 Significant	 variants	 tracking	 for	 each	 drug	 condition.	 Where	645 
mutations	 that	appear	at	any	given	 time-point	at	30%	or	more	are	plotted.	646 
Mutations	 listed	 in	 black	 appear	 in	 all	 three	 lineages,	 those	 in	 dark	 grey	647 
appear	 in	 two	 lineages	 and	 those	 in	 light	 grey	 only	 appear	 in	 one	 lineage.	648 (i)From	left	 to	right,	 	AMK	Lineage	A	(featuring	mutations;	cpxA	 (dark	green	fill):	649 Asp31Tyr	 circle,	 Trp184Arg	 square,	 fusA	 (mid-dark	 green	 fill):	 Pro610Gln	 up-650 triangle,	Pro610Thr	down-triangle;	sbmA	(lightest	green	fill):	asp194Asn	hexagon	651 with	 dot),	 B	 (featuring	 mutations	 cpxA	 (dark	 green	 fill):	 Asp31Tyr	 circle,	652 Trp184Arg	 square;	 fusA	 (mid-dark	 green	 fill):	 Pro610Gln	 up-triangle,	 sbmA	653 (lightest	 green	 fill):	 Asp194Glu	 circle	with	 dot)	 and	 C	 (featuring	mutations	 cpxA	654 (dark	green	 fill):	Asp31Tyr	diamond	with	dot,	Trp184Arg	square;	 fusA	 (mid-dark	655 green	 fill):	 Ala608Val,	 Pro610Gln	 up-triangle,	 Pro610Thr	 down-triangle,	656 Thr647Ala	square	with	diagonal	cross;	sbmA	(lightest	green	fill):	Trp250*	diamond	657 with	cross)	(ii)	From	left	to	right,	 	CHL	Lineage	A	(featuring	mutations;	rob	(mid-658 dark	 purple):	 Gly245Arg	 star),	 B	 (featuring	 mutations;	 acrR	 (light	 purple):		659 Ala156Ser	 circle	with	diagonal	 cross;	marR	 (mid-light	 purple):	Arg86Trp	 square;	660 
 
 
rob	 (mid-dark	 purple):	 Arg156His	 circle)	 and	C	 (featuring	mutations;	acrR	 (light	661 purple):	 Arg209fs	 hexagon;	marR	 (mid-light	 purple):	 Arg86Trp	 square,	 Gln110*	662 down-triangle;	rob	(mid-dark	purple):	Arg156His	circle).	(iii)	From	left	to	right,	CIP	663 Lineage	A	(featuring	mutations;	gyrA	 (mid-light	green):	asp87Tyr	circle,	Gly75Ser	664 up-triangle,	ser83del	square;	soxR	(dark	purple):	Ser126_Arg127delinSer	diamond	665 with	 cross),	 B	 (featuring	 mutations;	 gyrA	 (mid-light	 green):	 asp87Gly	 diamond,	666 ser83del	square;	rob	 (mid-dark	purple):	Arg156His	hexagon	with	diagonal	cross)	667 and	 C	 (featuring	mutations;	acrR	 (light	 purple):	 Ser25*	 hexagon;	gyrA	 (mid-light	668 green):	 Gly81Cys	 circle	 with	 diagonal	 cross,	 soxR	 (dark	 purple):	669 Arg127_Ser128delinsArg	down-triangle).	(iv)	From	left	to	right,	AMK-CHL	Lineage	670 A	 (featuring	 mutations;	 acrR	 (light	 purple):	 Lys55Glu	 circle;	 cpxA	 (dark	 green):	671 Ala187Thr	 square,	 Ile382_Thr383delinMetLeu	 up-triangle,	 Ser175Cys	 down-672 triangle;	 soxR	 (Dark	 purple):	 Ala18Glu	 hexagon,	 glu150fs	 square	 with	 diagonal	673 cross),	B	(A	(featuring	mutations;	acrR	(light	purple):	Asp157Asn	star,	Cys205Phe	674 square,	 Lys55Glu	 circle	 and	 Met175Arg)	 and	 C	 (featuring	 acrR	 (light	 purple):	675 Ala156Ser	 diamond	 with	 Ala156Ser,	 Arg209fs	 square	 with	 diagonal	 cross,	676 Lys55Glu;	 cpxA	 (dark	 green):	 Ala187Thr	 and	 soxR	 (dark	 purple)	 Ala18Glu	677 hexagon).	 (V)	 From	 left	 to	 right,	 CHL-CIP	 Lineage	 A	 (featuring	 mutations	 gyrA	678 (mid-light	 green):	 Phe96fs	 circle,	 Ser83del	 square;	 marR	 (mid-light	 purple):	679 Cys51Ser	 half-dark	 up-triangle,	 Val84Glu	 down	 triangle;	 soxR	 (dark	 purple):	680 Arg20Cys	square)	B	(featuring	mutations	acrR	(light	purple):	Cys205delinsCysArg	681 circle,	Thr5Ala	circle	half	dark;	gyrA	(mid-light	green):	Ser83del	square;	soxR	(dark	682 
 
 
purple):	 Arg20Cys	 square,	 Ser126_Arg127delinsCys	 diamond)	 and	 C	 (featuring	683 mutations	acrR	 (light	purple):	Cys205delinsCysArg	circle;	gyrA	 (mid-light	green):	684 Ser83del	 square;	 soxR	 (dark	 purple):	 Arg20Cys	 square,	 Ser126_Arg127delinsSer	685 up-triangle).	686 
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 14 
Abstract	15 
Cystic	 fibrosis	 (CF)	 patients	 due	 to	 inherited	 genomic	 mutations	 suffer	 from	16 dehydrated	 mucous	 that	 provide	 the	 perfect	 matrix	 to	 support	 opportunistic	17 pathogens.	This	is	of	critical	concern	in	the	lungs	where	infections	can	easily	occur	18 and	 debilitate	 lung	 function.	 	 Antimicrobial	 therapy	 has	 been	 good	 at	 delaying	19 chronic	 lung	 infections	 but	 despite	 best	 efforts,	 patients	 often	 become	 chronically	20 infected	 with	 chronic	 Pseudomonas	 aeruginosa	 in	 their	 lungs.	 Aggressive	21 antimicrobial	 treatment	 helps	 to	 lower	 the	 P.	 aerugionsa	 bacteria	 population	 to	22 restore	better	lung	function,	but	over-time	P.	aerugionsa	evolve	to	become	antibiotic	23 resistant	and	 the	 therapy	become	 less	effective	overtime.	This	 study	addresses	CF	24 patients	 that	are	 inflicted	with	chronic	Pseudomonas	aeruginosa	 lung	 infections	by	25 directly	analyzing	their	by	directly	analyzing	their	sputum	during	hospitalization	for	26 antimicrobial	 therapy.	 This	 is	 first	 study	 to	 directly	 analyze	 un-perturbed	 sputum	27 samples	 in	 19	 known	 antibiotic	 resistance	 and	 patho-adaptive	 genes	 (ampC,	28 
ampDh3,	fusA1,	fusA2,	gyrA,	gyrB,	mexR,	mexS,	mexT,	mexZ,	nfxB,	opr86,	phoP,	PhoQ,	29 
pmrA,	pmrB	and	rpoB)	 to	understand	abundance	of	 individual	mutational	 variants	30 and	mutational	variant	populations	effects.	By	using	whole	gene	sequencing	directly	31 on	 sputum	 samples	 from	 CF	 patient	 we	 yield	 important	 results	 regarding	 P.	32 
aeruginosa	 lung	population,	which	could	help	optimizing	antibiotic	treatments	and	33 reduce	 antibiotic	 resistance	 development	 in	 persistence	 and	 chronically	 P.	34 
aeruginosa	infected	CF	patients.		35 
	36 
Key	word:	Pseudomonas	aeruginosa,	cystic	fibrosis,	direct	whole	gene	population	37 sequencing,	sputum,	and	clonal	interference	38 
	39 
Introduction 40 
Cystic	fibrosis	(CF)	is	an	autosomal	recessively	inherited	disease	that	affects	about	7	41 in	100,000	people	in	the	EU	countries	(Farrell,	2008).	It	is	caused	by	a	mutation	in	42 the	 CFTR	 protein	 that	 function	 as	 a	 chloride	 channels	 causing	 viscous	 dehydrate	43 mucous	 on	 muco-epithial	 linings,	 which	 is	 difficult	 to	 expel.	 	 Un-expelled	 mucus	44 provides	 the	 perfect	 habitat	 for	 a	 consortium	 of	 opportunistic	 microorganisms	45 (Tang	 et	 al.,	 2014)	 and	 consequently	 lung	 infections	 are	 the	 major	 cause	 of	46 morbidity	 and	mortality	 in	 CF	 patients.	 Therefore,	 it	 is	 routine	 for	 CF	 patients	 to	47 have	 recurrent	 antimicrobial	 therapy	 to	 treat	 the	 lung	 infections	 and	 to	maintain	48 lung	 function	 (Johansen	 et	 al.,	 2004).	 Antimicrobial	 therapy	 has	 help	 to	 delay	 the	49 development	 of	 chronic	 infections	 from	 infancy	 to	 early	 adolescents	 ages	 (Döring	50 and	Hoiby,	2004;	Frederiksen	et	al.,	1997;	Valerius	et	al.,	1991).	However,	CF	patient	51 often	become	infected	with	ubiquitous	environmental	bacterial	pathogen,	especially,	52 
Pseudomonas	aeruginosa,	which	often	becomes	established	as	a	chronic	infection.	53 
	54 
Many	 studies	 focus	 on	 the	 adaptive	 process	 of	 P.	 aeruginosa	 to	 becoming	 an	55 established	chronic	infection	(Marvig	et	al.,	2015;	Smith	et	al.,	2006;	Sommer	et	al.,	56 
2016)	 or	 developing	 resistance	 against	 antimicrobial	 therapy	 (Feng	 et	 al.,	 2016;	57 Jochumsen	et	al.,	2016).		58 
	59 
Here	we	present	an	in-vivo	molecular	study,	following	four	CF	patients	hospitalized	60 for	antimicrobial	 treatment.	By	directly	extracting	 the	DNA	 from	the	sputum	 from	61 three	 time-points	 at	 day	 0,	 7,	 and	 14;	 we	 can	 observe	 the	 un-biased	 mutational	62 variants	that	are	occur	within	the	genes	by	using	our	molecular	pipeline	(Figure	1).	63 Our	 pipeline,	 unlike	 other	 proceeding	 studies	 analyzes	 the	 whole	 gene,	 by	 PCR	64 amplification	up	and	downstream	of	our	genes	of	interest.	With	the	information,	we	65 can	 access	 the	 amount	 of	 mutated	 alleles	 occurring	 at	 each	 time	 point	 and	 state	66 what	translational	effect	they	cause.	By	understanding	the	population	dynamics	and	67 mutational	 alleles	 that	 are	 enriched	 during	 antimicrobial	 therapy	we	 can	 acquire	68 knowledge	 about	 bacterial	 populations	 that	 can	 be	 targeted	 in	 CF	 patients	 with	69 chronic	P.	aeruginosa	 infections.	Future	application	for	CF	patients	 from	this	study	70 are:	 deployment	 of	 antimicrobial	 treatment	 that	 reduced	 the	 evolution	 of	71 antimicrobial	 resistance;	 and	 for	 CF	 patients	 that	 suffer	 from	 persistent	 P.	72 
aeruginosa	infections,	with	the	motivation	how	to	delay	chronic	colonization.	73 
	74 
Material	and	methods	75 
	76 
Patient	77 
Our	 study	consisted	of	4	males	CF	patients	undergoing	antimicrobial	 treatment	at	78 the	CF	clinic	at	Rigshospitalet,	Copenhagen,	Denmark.	The	age	of	the	patients	ranged	79 from	 26	 to	 53	 years,	 all	 were	 diagnosed	 with	 chronic	 P.	 aeruginosa	 infection	 in	80 accordance	to	the	Copenhagen	criteria	(Johansen	et	al.,	2004).	Patient’s	treatment	at	81 the	 hospital	 is	 recorded	 in	 (Table	 1).	 Samples	were	 stored	 at	 -20	 after	 collection,	82 until	DNA	extraction	was	performed.	83 	84 
Microbiology	85 
All sputum samples were Gram-stained and microscopically evaluated and 86 
cultured aerobically on selective agar media. These media include a Sabouraud 87 
plate, a 7% NaCl plate, a B. cepacia plate containing colistin and gentamicin and a 88 
“blue plate” (modified Conradi Drigalski's medium) selective for Gram-negative 89 
rods and non-selective media including 5% Danish blood agar and chocolate agar. 90 
Direct plating of sputum samples on a 14-cm blood agar plate (State Serum 91 
Institute, Copenhagen, Denmark) with discs containing anti-pseudomonas 92 
antibiotics including colistin, tobramycin, meropenem, ciprofloxacin, aztreonam, 93 
piperacillin/tazobactam and ceftazidime. Susceptibility testing of the sputum 94 
samples was done by the agar diffusion method on Danish blood agar plates 95 
(Statens Serum Institut, Copenhagen, Denmark), employing Neosensitabs® 96 
(Rosco, Roskilde, Denmark)(Ciofu et al., 1996). Isolated bacteria were identified 97 
as described previously (Johansen et al., 2008) Before 2011, biochemical profiling of P. 98 
aeruginosa was based on API 20NE (bioMérieux), and from 2011 on MALDI-TOF mass 99 
spectrometry (Bruker, Germany). 100 
	101 
	102 	103 
DNA	extraction	from	sputum	samples	104 All	 thawed	 sputum	 samples	 were	 treated	 with	 30µL	 (1M)	 tris	 (2-carboxyethyl)	105 phosphine,	and	10µL	proteinase	K	(20mg/mL)	(ThermoFisher	Scientifc)	and	1mL	of	106 DNA/RNA	shield	(Zymo	Research)	and	vortexed	for	30	seconds.	Samples	were	then	107 added	 to	 a	 2mL	 impact	 resistant	 screw-top	 tube	with	 300mL	 zirconia/glassbeads	108 with	 a	 diameter	 0.1mM	 (Carl	 Roth	 International) and	 vortexed	 on	 a	 secure	 and	109 horizontal	holder	at	maximum	speed	for	5	mins.	Then	genomic	DNA	was	extracted	110 from	all	sputum	samples	by	ZR	–Duet	RNA/DNA	mini-prep	kit	(Zymo	Research)	and	111 done	in	accordance	to	the	kits	recommendations.	 112 
	113 
Primer	Design	114 
The	genes	selected	were	chosen	based	on	knowledge	of	their	 involvement	de-novo	115 antibiotic	 resistance.	 The	 following	 genes	 of	 the	 P.	 aeruginosa	 core	 genome	were	116 selected	 for	 sequencing:	 ampC,	 ampDh3,	 ftsI,	 fusA1,	 fusA2,	 gyrA,	 gyrB	mexS,	mexR,	117 
mexT,	mexZ,	nfxB,	opr86,	parC,	pmrA,	pmrB,	phoQ,	phoR,	rpoB.	Primers	were	designed	118 to	amplify	19	genes	associated	with	antibiotic	susceptibility	(Supplemental	Fig.	1).	119 All	primers	were	 tested	with	genomic	DNA	 from	P.	aeruginosa	 strains:	PAO1,	DK2	120 and	 PA14	 the	 sequences	 of	 the	 19	 target	 genes	 were	 extracted	 from	 the	121 Pseudomonas	database	(Winsor	et	al.,	2016).	PCR	products	were	tested	with	PAO1	122 
and	 DK-2	 DNA	 extracts	 verified	 by	 1%	 agarose	 gel	 electrophoresis	 with	 GelRed	123 (Biotium).	124 
 125 
Whole	gene	library	preparation	and	sequencing		126 
All	 samples	were	amplified	using	 the	19	primer	pairs	 in	 (Supplemental	 table	 1),	127 PCRs	 from	 sample	DNA	 extracts	were	 done	 independently	 to	 each	 other	 to	 avoid	128 cross	 contamination.	 Each	PCR	 reaction	was	done	 in	 0.2mL	 sterile	 PCR	 tubes	 and	129 consists	of	10	µ	L	Phusion	High-Fidelity	PCR	master	mix	(Thermo	Fischer	Scientific),	130 0.5	µM	 forward	primer,	 0.5	µ	M	 reverse	primer,	 1	µL	DNA	 template	 and	H20	 to	 a	131 total	reaction	volume	of	20	µL.	The	PCR	amplification	used	an	initial	denaturation	of	132 for	 98oC	 30	 seconds,	 30	 cycles	 consisting	 of	 a	 98oC	 for	 10	 seconds	 denaturation,	133 60oC	 for	10	seconds	annealing,	72oC	 for	3	min	elongation,	72oC	 final	extension	 for	134 180	seconds	then	hold	at	4oC.	To	validate	correct	amplification	gel	electrophoresis	135 was	performed	with	a	96-well	2%	E-gel	with	SYBR	safe	DNA	gel	stain	(Invitrogen)	136 on	 the	 E-base	 electrophoresis	 device	 for	 13	 min	 (Invitrogen)	 and	 gel	 images	137 analyzed	on	the	E-editor	2.02	software	(Invitrogen).	Each	sample	was	cleaned	with	138 1.8x	 Ampure	 bead	 and	 done	 in	 accordance	 an	 online	 protocol	 (Beckman	 Coulter	139 2013).	 The	 19	 PCR	 reactions	 for	 each	 sample	 DNA	 extract	were	 pooled	 together;	140 each	pooled	PCR	product	in	accordance	to	its	original	sample.	200ng	of	pooled	DNA	141 in	a	volume	of	130µL	was	sheared	in	a	Covaris	focused-ultrasonicator	E220,	for	55	142 seconds	with	a	peak	incidence	power	of	105W,	duty	factor	5%	and	cycles	per	burst	143 200.	Sheared	pooled	DNA	samples	were	then	prepared	for	sequencing	by	the	Kapa	144 
Hyper	Plus	DNA	library	preparation	kit	(Kapa	Biosystems)	and	barcoded	using	LT-145 Truseq	 single-index	 adapter	 kit	 (Illumina	 Inc).	 Barcoded	 libraries	were	measured	146 for	 DNA	 concentration	 with	 Qubit	 dsDNA	 HS	 Assay	 kits	 and	 measured	 on	 Qubit	147 Fluorometer	 (Thermo	Fischer	Scientific	 Inc	2015)	and	average	 fragment	 size	with	148 Fragment	 analyzer	 (Advanced	 Analytical	 Technologies,	 Inc).	 Barcoded	 libraries	149 were	pooled	from	fragment	size	and	DNA	concentration	values	to	form	a	sequencing	150 library	 based.	 The	 sequencing	 library	was	 sequenced	 on	 the	MiSeq	 platform	with	151 Miseq	reagent	kit	V3,	sequence	read	length	2x300bp	(Illumina	Inc).	152 
	153 
Sequence	Analysis	154 
All	 raw	 sequencing	 read	 from	 the	 gene	 sequencing	 has	 been	 deposited	 in	 the	155 Sequence	Read	Archive	(SRA)	under	bioproject	accession	number	xxxx.	Sequencing	156 reads	were	mapped	to	the	reference	genome	(GenBank	accession	AE004091)	using	157 CLC	 genomics	 workbench	 version	 8.5.1(Qiagen).	 To	 verify	 sequencing	 coverage,	158 mapping	 read	 files	 from	CLC	 genomic	workbench	data	was	 analyzed	 in	 Excel	 and	159 plots	 designed	 in	 Prism	6	 (GraphPad	 Software	 Inc).	 To	 ensure	 good	 coverage	 our	160 threshold	for	average	coverage	was	set	at	100,	samples	that	had	low	coverage	were	161 re-read	 until	 sufficient	 coverage	was	 achieved	 (Supplemental	 Fig	 1-4).	 	 Variants	162 were	detected	by	using	the	low	frequency	variant	detection	calling	function	in	CLC	163 genomic	workbench	V	8.5.1	(Qiagen),	provide	all	the	variants	that	had	a	population	164 frequency	of	≥1%.	(Supplemental	Table	2).		165 
	166 
Results	167 
The	 study	 consisted	 of	 4	 CF	 patients	 chronically	 with	 P.	 aerugionsa	 with	 an	 age	168 range	from26	to	53	years.	Each	patient	provided	three	sputum	samples	on	day	0,	7	169 and	 14	 during	 hospitalized	 antimicrobial	 treatment,	 minus	 one	 patient	 who	 was	170 unable	to	provide	a	day	7	cough	sample.	Following	our	pipeline	we	extracted	DNA	171 from	 each	 of	 the	 samples	 and	 using	 our	 pipeline	 (Figure	 1)	 the	 intrinsic	172 antimicrobial	 resistance	 development	 was	 assessed	 in	 19	 genes	 that	 have	 been	173 previously	reported	to	confer	resistance	against	certain	classes	of	antibiotics.	These	174 were:	for	aminoglycoside	(genes	of	interest	were:	fusA1	(Marvig	et	al.,	2013),	fusA2	175 (Marvig	 et	 al.,	 2013),	 and	 rpoB	 (Qi	 et	 al.,	 2014));	 for	 peptidoglycan	 synthesis	176 inhibiting	classes	(genes	of	interest	were:	ampC	(Marvig	et	al.,	2013)	,	ampDh3	(Lee	177 et	 al.,	 2013)	 and	 ftsI	 (Smith	 et	 al.,	 2006));	 	 for	 fluoroquinolone	 (genes	 of	 interest	178 were:	gyrA	(Feng	et	al.,	2016;	Marvig	et	al.,	2013),	gyrB	(Feng	et	al.,	2016;	Marvig	et	179 al.,	2013),	parC	(Feng	et	al.,	2016)	and	rpoB	(Pietsch	et	al.,	2017));	polymixin	(genes	180 of	 interest	 were:	 opr86	 (Jochumsen	 et	 al.,	 2016),	 phoP	 (Smith	 et	 al.,	 2006)	 phoQ	181 (Gutu	et	al.,	2013;	Moskowitz	et	al.,	2012),	pmrA	(Moskowitz	et	al.,	2012)	and	pmrB	182 (Moskowitz	et	al.,	2012;	Smith	et	al.,	2006));	and	patho-adaptive	genes	that	confer	183 cross-resistance	 (genes	 of	 interest	 were:	 mexR	 (Vestergaard	 et	 al.,	 2016),	184 
mexS(Richardot	et	al.,	2016),	mexT	(Smith	et	al.,	2006),	mexZ	(Smith	et	al.,	2006)	and	185 
nfxB	(Monti	et	al.,	2013)).	186 
	187 
	Only	 two	 patients	 provide	 a	 day	 0	 and	 day	 14	 samples	 for	 antimicrobial	188 susceptibility	 testing	 samples	 to	 the	 department	 of	 clinical	 microbiology	189 department,	these	were	patient	CF156	and	CF83	(Table	2).		From	the	antimicrobial	190 susceptibility	 testing	 we	 observed	 phenotypic	 changes	 before	 and	 after	 in	 both	191 patients.	 For	 CF156	 in	 the	 non-mucoid	P.	aeruginosa	 we	 saw	 changes	 in:	 colistin,	192 from	 susceptible	 to	 resistant;	 imipenem,	 from	 susceptible	 to	 intermediate;	 and	193 meropenem,	and	from	intermediate	to	resistant.	In	the	same	patient	we	also	saw	in	194 the	mucoid	P.	aeruginosa	sample	a	phenotypic	change	of	impenem	from	day	0	being	195 intermediate	 to	 susceptible	on	day	14.	Whereas	 for	patient	CF83	 in	 the	mucoid	P.	196 
aeruginosa	 antimicrobial	 susceptible	 typing	 results	 we	 saw	 changes	 in:	197 ciprofloxacin,	 from	susceptible	to	intermediate;	and	imipenem,	from	susceptible	to	198 intermediate.	 The	 overall	 observation	 from	 these	 two	 patients	 is	 that	 the	 use	199 antimicrobial	therapy	leads	to	induction	of	resistance	to	several	antibiotics.	This	is	200 not	surprising	as	antimicrobials	are	well	know	for	selecting	pre-existing	and	de-novo	201 mutants	(Andersson	and	Hughes,	2014).		202 
	203 
Detection	 of	 mutational	 variants	 reveal	 the	 high	 abundance	 of	204 
mutagenic	events	of	P.	aeruginosa	in	the	CF	lung	205 Following	coverage	analysis,	where	all	samples	had	to	meet	the	requirements	of	all	206 genes	 having	 an	 average	 coverage	 of	 100	 sequencing	 reads	 per	 base	 in	 the	 open	207 reading	frame	of	the	gene,	the	variant	detection	and	analysis	was	performed.	From	208 our	 results	 we	 able	 to	 plot	 an	 overview	 of	 all	 the	 variant	 types	 detected	 with	 a	209 population	 frequency	≥5%	 for	 each	patient	 and	 time-point	 (Figure	2).	 From	 these	210 plots,	 we	 found	 that	 the	 maximum	 total	 individual	 variant	 detected	 were	 was	 in	211 
patient	 CF382	 at	 day	 0	 with	 514	 different	 variants	 detected	 and	 the	 minimum	212 individual	 variant	 detected	 in	 patient	 CF83	 at	 day	 0	 with	 143	 different	 variants	213 detected.	 Most	 of	 the	 detected	 variants	 were	 synonymous	 mutations,	 the	 second	214 most	 abundant	mutation	 type	was	 non-	 synonymous	 SNPs,	 followed	 by	 the	 third	215 most	 abundant	 mutation	 type	 being	 frameshift	 mutations	 and	 the	 fourth	 most	216 abundant	mutation	type	was	premature	stop	mutations	where	few	to	no	mutations	217 were	 detected.	 	 Similar	 distribution	 of	 mutational	 variant	 types	 from	 amplicon	218 sequenced	P.	aerugionsa	isolates	from	the	CF	lung	have	been	reported	by	Grieple	et	219 al.	2016.		220 	221 There	was	 also	 a	 general	 trend	 amongst	 three	 of	 the	 patients	 that	 the	 amount	 of	222 individual	 mutation	 variants	 detected	 increased	 during	 the	 14-day	 antimicrobial	223 treatment.	 This	 was	 highest	 in	 patient	 CF83	 where	 the	 individual	 mutational	224 variants	 for	 day	 0,	 7	 and	 14	 were:	 143;	 173;	 and	 233	 (Figure	 2	 (iv)).	 In	 patient	225 CF243	 the	 individual	mutational	 variants	detected	 for	day	0,	 7	 and	14	were:	 253;	226 204;	 and	 305	 (Figure	 2	 (iii)).	 In	 patient	 CF243	 the	 individual	mutational	 variants	227 detected	for	day	0,	7	and	14	were:	175;	156;	and	201	(Figure	2	(ii)).	An	exception	to	228 this	trend	was	patient	CF382,	where	the	individual	mutational	variants	detected	for	229 day	 0	 and	 14	 were	 514	 and	 158	 (Figure	 2	 (i)).	 These	 results	 imply	 that	 when	230 patients	are	receiving	antimicrobial	 therapy	 the	P.	aeruginosa	bacterial	population	231 in	the	lung	experiences	possibly	an	expansion	in	genomic	diversity.		Whether	this	is	232 a	 direct	 or	 downstream	 effect	 of	 antibiotics,	 such	 as	 the	 production	 of	 reactive	233 oxygen	 species	 (Kohanski	 et	 al.,	 2007)	 or	 by	 antibiotics	 inducing	 the	 quorum	234 sensing	mechanisms	endogenous	 to	P.	aeruginosa	that	 can	have	pleiotropic	effects	235 (Skindersoe	et	al.,	2008)	need	to	be	further	elucidated.		236 
	237 
Evaluation	 of	 non-synonymous	 mutations	 during	 antimicrobial	238 
treatment	 show	 mutational	 enrichment	 and	 clonal	 inference	239 
within	the	bacterial	population		240 We	 then	 further	 analyzed	 our	 data	 by	 evaluating	 the	 non-synonymous	mutations,	241 we	were	 interested	 to	 follow	the	 trajectories	of	mutations	 that	were	enriched	and	242 un-selected	 for	 during	 antimicrobial	 therapy	 (Figure	 3).	 To	 achieve	 this	 we	243 examined	 the	 non-synonymous	 mutations	 that	 were	 present	 at	 a	 least	 one	 time-244 point	 ≥5%.	 	 In	 this	 figure,	 we	 could	 see	 in	 all	 patients	 that	 there	 was	 a	 clear	245 enrichment	of	mutagenic	allelic	variants	over	the	treatment	time	period	(Figure	3A	246 (i-iv)).	We	were	 interested	 if	 these	mutations	had	been	previously	detected	and	 if	247 there	 was	 any	 information	 regarding	 these	 mutations	 conferring	 antibiotic	248 resistance.	 From	 the	 41	 non-	 synonymous	 mutations,	 11	 of	 these	 have	 been	249 reported	 in	 literature,	 with	 3	 mutations	 all	 from	 patient	 CF382	 with	 results	250 confirming	that	these	mutations	confer	resistance	(Table	3).	Our	molecular	pipeline	251 detected	 several	mutations	 that	 have	 not	 previously	 been	 reported,	 this	 could	 be	252 due	 to	 our	 direct	 DNA	 extraction,	 amplification	 and	 sequencing,	 capturing	 all	253 present	variants.	254 
	255 
From	the	enriched	mutation	variants,	we	could	see	that	each	patient	had	a	unique	256 response	in	the	individual	variants	that	were	produced.	This	could	be	a	result	of	the	257 historical	contingency	of	the	P.	aeruginosa	bacteria	in	the	lung,	the	clone-type	they	258 were	infected	with	and	the	treatment	used	(Table	1).	Patient	CF382	is	known	to	be	259 
infected	 with	 a	 hypermutator	 strain,	 and	 was	 treated	 with	 drug	 classes:	260 aminoglycosides,	cephalosporin,	 fluoroquinolone	and	polymixins.	Therefore,	 it	was	261 not	 surprising	we	 saw	enriched	mutations	 in	 the	 following	 genes:	ampC,	ampDh3,	262 
fusA1,	 fusA2,	 gyrA,	 gyrB,	mexZ,	 opr86,	 phoQ,	pmrA,	pmrB	 and	 rpoB.	For	 CF156,	 the	263 patient	 was	 treated	 with	 polymixin	 and	 fluoroquinole	 classes	 of	 antibiotics.	 This	264 patient	had	enriched	mutations	in:	ampC,	ampD3h,	mexT,	opr86,	pmrA	and	rpoB.	The	265 
ampC	and	ampD3h	mutations	that	were	enriched	during	treatment	were	an	anomaly	266 we	didn’t	expect	to	observe,	as	the	ampC	and	ampDh3	mutations	we	expect	to	confer	267 beta-lactam,	cephalosporin	and	carbapenem	resistance.	We	suspect	that	these	new	268 mutants	 in	 mexT,	 opr86,	 pmrA	 and	 rpoB	 that	 appeared	 had	 ampC	 and	 ampDh3	269 mutations	 in	 their	 genomic	background,	 and	were	 selected	 as	 a	 result	 of	 genomic	270 hitchhiking	 a	 common	 phenomenon	 often	 seen	 in	 adaption	 laboratory	 evolution	271 experiments	 (Elena	 and	 Lenski,	 2003).	 Patient	 CF243	 was	 treatment	 with	272 aminoglycosides,	carbapenem,	fluoroquinolone	and	polymixin	classes	of	antibiotics.	273 The	high	levels	of	enrichment	consisted	in	mutations	in	pmrB	gene	that	is	known	to	274 confer	 resistance	 to	 polymixins	 (Moskowitz	 et	 al.,	 2012;	 Owusu-Anim	 and	 Kwon,	275 2012;	Schurek	et	al.,	2009)	and	mexT,	which	is	known	to	confer	cross-resistance	by	276 the	 expression	 of	 efflux	 pumps	 (Alyaseen	 et	 al.,	 2005).	 Patient	 CF83	 was	 treated	277 with	 aminoglycosides,	 cephloasporin,	 fluoroquinolones	 and	 polymixins.	 High	278 frequency	enrichment	was	found	in	rpoB,	mexT,	and	ftsI	and	low-level	enrichment	in	279 
mexS	and	gyrA.	Where	the	rpoB	mutants	confer	aminoglycoside	resistance	(Qi	et	al.,	280 2014)	and	ciprofloxacin	(Pietsch	et	al.,	2017),	ftsI	mutants	confer	resistance	against	281 
carbapenems	 (Cabot	 et	 al.),	 and	 mexT	 mutants	 provide	 general	 cross-resistance	282 (Alyaseen	et	al.,	2005).	283 
	284 
We	also	observed	strong	clonal	interference	is	exhibited	in	two	patients,	CF382	and	285 CF83	 (Figure	3A	 (i)	 and	 (iv),	3B	 (i)	 and	 (iv)),	with	marginal	 clonal	 interference	 in	286 CF156	and	CF243	(Figure	3A	(ii)	and	 (iii),	3B	 (i)	and	 (iv)).	 	 In	all	patients,	we	see	287 that	there	are	sub-populations	of	bacterial	mutational	variants,	a	trait	also	seen	by	288 others	regarding	sub-populations	of	virulent	P.	aeruginosa	in	the	CF	lung	(O’Brien	et	289 al	 2017).	 Therefore,	 establishment	 of	 novel	mutations	 seems	 to	 readily	 occur,	 but	290 fixation	 in	 the	 population	 is	 a	 rare	 event,	 unlike	 in-vitro	 adaptation	 evolution	291 experiments	in	other	Gram-negative	species	(Wong	and	Seguin,	2015).	This	could	be	292 an	 artifact	 of	 spatial	 structural	 and	heterogeneity	 in	 the	CF	 lung	 (Folkesson	 et	 al.,	293 2012;	Markussen	et	al.,	2014;	Winstanley	et	al.,	2016)	or	the	short	time	period	our	294 study	was	preformed	in.	Thus,	showing	the	complex	bacterial	population	dynamics	295 within	CF	patients.		296 
	297 
Discussion	298 
Within	 this	 study	 we	 use	 whole	 gene	 population	 sequencing	 method	 to	 study	299 individual	 mutation	 variant	 events	 and	 mutagenic	 populations	 dynamics.	 Our	300 approach	was	to	extract	the	DNA	from	the	patient	sputum	samples,	amplify	genes	of	301 interest	 and	 sequence	 with	 no	 P.	 aerugionsa	 isolation	 cultivation	 steps.	 With	 the	302 
development	 and	 growing	 accessibility	 of	 next	 generation	 sequencing	 platforms,	303 studies	 analyzing	 evolution	 in	 bacterial	 populations	 are	 growing.	 In	 particular,	 P.	304 
aerugionsa	 population	 sequencing	 following	 cultivation	 from	 CF	 patient	 samples	305 (Fischer	et	al.,	2016;	Greipel	et	al.,	2016;	O’Brien	et	al.,	2017).	306 
	307 
In	CF	patients	that	are	chronically	infected	with	P.	aeruginosa,	we	have	observed	the	308 vast	array	of	mutant	clones	occupy	one	environment,	a	phenomenon	also	described	309 by	Greiple	 et	 al	 2016.	 Yet	 by	 following	 events	 longitudinally	we	 can	 observe	 how	310 these	 compete	 by	 clonal	 interference	 to	 establish	 the	 clone	 types	 that	 best	 aids	311 population	survival.			312 
	313 
The	 bacterial	 populations	 we	 study	 also	 display	 similar	 characteristics	 that	 have	314 been	 reported	 in-vitro	 adaptation	 studies	 with	 other	 Gram-negative	 bacterial	315 species,	 such	 as	 clonal	 interference	 and	multiple	mutant	 enrichment	 (Fogle	 et	 al.,	316 2008;	Gerrish	and	Lenski,	1998;	Sniegowski	et	al.,	1997;	Wong	and	Seguin,	2015).		317 
	318 
Our	results	are	important	but	limited	therefore	in	future	we	would	like	to	examine	a	319 larger	cohort	of	chronically	infected	patient	and	for	longer	periods	of	time.	This	will	320 allow	 us	 to	 examine	 key	 factors	 such	 as:	 which	 antibiotics	 treatment	 cause	 the	321 highest	 and	 lowest	 generation	of	mutational	 variants;	 and	by	 studying	population	322 
dynamics	 for	 longer	periods	of	 time	can	we	capture	clonal	 fixation	events	and	 the	323 implications	of	these	population	fixations	by	in-vitro	experimentation.		324 
	325 
Therefore,	 our	 long-term	 version	 is	 to	 optimize	 antimicrobial	 treatment	 in	326 chronically	 infected	 CF	 patients	 with	 P.	 aeruginosa	 and	 in	 patients	 that	 have	327 persistent	colonization	and	 find	strategies	 to	delay	 the	chronic	establishment	of	P.	328 
aeruginosa.		329 
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	512 
Figure	Legends	513 
Figure	1.	Methodology	workflow	overview	 (1)	Thaw	collected	sputum	samples,	514 (2)	Extract	DNA	 from	each	 sample	 (3)	PCR	all	19	genes	 for	each	DNA	extract	 and	515 verify	PCR	products	(4)	Shear	DNA	by	sonication	for	DNA	fragments	ca.	600bp	(5)	516 Prepare	 sequencing	 library	 by	 kit	 and	 barcode	 then	 pool,	 (6)	 Sequence	 Miseq	517 Illumina	platform.	518 	519 
Figure	2.	Overview	of	all	variant	 types	detected	with	a	population	 frequency	520 
≥5%	throughout	treatment	course	for	all	genes	combined	(i)	Patient	CF382,	(ii)	521 CF156,	(iii)	CF243	and	(iv)	CF83.	Variant	types	correspond	to	key	on	the	right.		522 	523 
Figure	 3.	 Enriched	 and	 unselected	 variant	 alleles	 throughout	 treatment	 for	524 
each	 patient	 (A)	Enriched	variant	 alleles	during	 treatment	 (i)	 Patient	CF382,	 (ii)	525 CF156,	(iii)	CF243	and	(iv)	CF83.	variant	types	correspond	to	key	on	the	right.	(B)	526 Unselected	variant	alleles	during	treatment	(i)	Patient	CF382,	(ii)	CF156,	(iii)	CF243	527 and	(iv)	CF83.	Each	variant	is	listed	on	the	right	of	each	plot.	528 	529 		530 
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Table	1.	Patient	history	543 
Patient Daily treatment over hospitalization 
period 
P. aeruginosa 
Clone Type 
Hypermutator 
strain 
CF382 Intravenous	3g	Ceftazidime	3g	x	3	Intravenous	500	mg	Tobramycin	x	1	Inhalation	Promixin	3	mio	IE	x	1	Oral	750	mg	Ciprofloxacin	x	2	Oral	250	mg	Azithromycin	x	1	
DK32	 Yes	
CF156 Oral 750	mg	Ciprofloxacin	x	2	Intravenous	9	mio	IE	Colistin	x1	 DK1 and DK2  No 
CF243 Intravenous	9	mio	IE	Colistin	x1	Intravenous	2g	Meropenem	x	2	Inhalation	240mg	Ciprofloxacin	x	2	Inhalation	300mg	Tobramycin	x	2	Oral	250	mg	Azithromycin	x	1	
DK2	 No	
CF83 Inhalation	Promixin	3	mio	IE	x	1	Intravenous	3g	Ceftazidime	3g	x	3	Intravenous	500mg	Tobramycin	x	1	Inhalation	Promixin	3	mio	IE	x	1	Oral	750mg	Ciprofloxacin	x	2	Oral	250mg	Azithromycin	x	1 
Unknown	 No	
 544 
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	546 
	547 
	548 
	549 
	550 
	551 
	552 
	553 
	554 
	555 
	556 
	557 
Table	2.	Antimicrobial	susceptibility	testing	of	each	of	patient	558 	559 Patient	 Time-point	 P.	aeruginosa	type	 Antimicrobial	 Antimicrobial	susceptibility	type	CF382	 Day	0	 Mucoid									Non-Mucoid		
Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	
R	I	S	S	R	R	R	I	S	R	I	S	S	R	I	R	I	S		CF156	 Day	0																		Day	14	
Mucoid									Non-mucoid									Mucoid			
Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	Aztreonam	Ceftazidime	Ciprofloxacin	
R	R	S	S	I	I	R	I	S	R	R	S	S	S	I	R	R	I	R	R	S	
						Non-mucoid	
Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	
S	S	I	R	I	S	R	R	S	R	I	R	R	R	S	CF243	 Day	0		 Non-mucoid		 Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	
R	R	R	S	R	R	R	I	R	CF83	 Day	0									Day	14	
Mucoid									Mucoid	
Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	Aztreonam	Ceftazidime	Ciprofloxacin	Colistin	Imipenem	Meropenem	Moxifloxacin	Piperacillin	+	Tazobactam	Tobramycin	
S	S	S	S	S	S	R	S	S	S	S	I	S	I	S	R	S	S	
	560 
	561 
Table	3.	Enriched	non-synonymous	mutations	that	are	reported	in	literature	562 Patient	 Gene	 Amino	Acid	Change	 Literature	 Reported	MIC	increase	CF382	 ampC	 Thr105Ala	 (Rodríguez-Martínez	 et	al.,	2009)		
Cefapime	->64	fold		Cefepime	->8	fold	Imipenem	->	10	fold	Meropenem	->	2	fold	CF83	 ftsI	 Arg503Cys	 (Cabot	et	al.,	2016)	 	CF382	 fusA2	 Gln610His	 (Greipel	et	al.,	2016)	 	CF382	 gyrA	 Ala51Val	 (Greipel	et	al.,	2016)	 	CF382	 gyrB	 Ser466Phe	 (Bruchmann	 et	 al.,	2013)	(Llanes	et	al.,	2011)	
Ciprofloxacin->	10	fold	
CF382	 pmrA	 Leu71Arg	 (Bezuidt	et	al.,	2013)	(Schurek	et	al.,	2009)	 	CF382	 pmrB	 Ala282Thr	 (Moskowitz	et	al.,	2012)	 Colistin->	8	fold	CF382	 pmrB	 Tyr345His	 (Owusu-Anim	 and	Kwon,	2012)	 	CF83	 rpoB	 Arg1038His	 (Greipel	et	al.,	2016)	 	
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